Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CSTL

Castle Biosciences Inc

Feb 17 • 01:45PM ET

33.48

+0.33 1.00 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: GH EXAS FLGT CDNA MYGN NTRA QDEL DGX ILMN TXG

| Held by: VTI IWM VXF IWN IBB VTWO SCHA BSVO VHT DFAT

Index	RUT	P/E	-	EPS (ttm)	-0.45	Insider Own	2.65%	Shs Outstand	29.16M	Perf Week	3.88%
Market Cap	977.24M	Forward P/E	-	EPS next Y	-1.29	Insider Trans	-19.18%	Shs Float	28.41M	Perf Month	-17.84%
Enterprise Value	726.84M	PEG	-	EPS next Q	-0.26	Inst Own	88.78%	Short Float	5.33%	Perf Quarter	-1.88%
Income	-12.24M	P/S	2.84	EPS this Y	-267.54%	Inst Trans	-3.15%	Short Ratio	3.75	Perf Half Y	66.65%
Sales	343.53M	P/B	2.09	EPS next Y	-23.80%	ROA	-2.27%	Short Interest	1.51M	Perf YTD	-13.93%
Book/sh	16.02	P/C	3.40	EPS next 5Y	-	ROE	-2.69%	52W High	44.28 -24.39%	Perf Year	22.55%
Cash/sh	9.85	P/FCF	30.48	EPS past 3/5Y	- -	ROIC	-2.43%	52W Low	14.59 129.47%	Perf 3Y	28.77%
Dividend Est.	-	EV/EBITDA	92.83	Sales past 3/5Y	52.25% 44.97%	Gross Margin	68.58%	Volatility	4.21% 4.94%	Perf 5Y	-62.87%
Dividend TTM	-	EV/Sales	2.12	EPS Y/Y TTM	-295.52%	Oper. Margin	-10.17%	ATR (14)	1.74	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.31	Sales Y/Y TTM	10.15%	Profit Margin	-3.56%	RSI (14)	35.08	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	6.47	EPS Q/Q	-122.28%	SMA20	-10.02%	Beta	1.08	Target Price	48.12
Payout	0.00%	Debt/Eq	0.08	Sales Q/Q	-3.19%	SMA50	-13.12%	Rel Volume	0.23	Prev Close	33.15
Employees	761	LT Debt/Eq	0.08	Earnings	Feb 26 AMC	SMA200	27.07%	Avg Volume	404.31K	Price	33.48
IPO	Jul 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	96.16% 16.79%	Trades		Volume	61,081	Change	1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Guggenheim	Buy	$25
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$54
Jan-07-22	Initiated	Stephens	Overweight	$59
Apr-30-21	Initiated	Lake Street	Buy	$94
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$70
Dec-27-19	Reiterated	Canaccord Genuity	Buy	$34 → $35
Aug-19-19	Initiated	SVB Leerink	Outperform	$28
Aug-19-19	Initiated	Robert W. Baird	Outperform	$27
Aug-19-19	Initiated	Canaccord Genuity	Buy	$26
Aug-19-19	Initiated	BTIG Research	Buy	$25

Today 10:05AM	Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? (Zacks)
09:48AM	Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
09:15AM	Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Feb-13-26 12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:33AM	Loading…
10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
Feb-12-26 10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
Feb-11-26 10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
Feb-10-26 10:45AM	Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks)
10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
10:22AM	Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect (Zacks)
09:35AM	Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
07:51AM	Loading…
07:51AM	Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-06-26 11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks) -7.32%
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
08:31AM	AstraZeneca to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
07:00AM	Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 (GlobeNewswire)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks) -10.22%
Feb-03-26 05:20PM	AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit (Motley Fool)
11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
08:30AM	CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
Jan-30-26 08:47AM	Viking Therapeutics to Report Q4 Earnings: Here's What to Know (Zacks)
Jan-28-26 09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks) -7.77%
10:50AM	Loading…
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
Jan-23-26 12:00PM	Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice (Zacks)
Jan-11-26 04:00PM	Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
Jan-02-26 10:54AM	AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation (Zacks)
08:15AM	INSM Stock Up 78% in 6 Months: Here's What You Need to Know (Zacks)
Dec-31-25 09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
Dec-30-25 11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
Dec-29-25 10:17AM	Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus (Zacks)
09:53AM	Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? (Zacks)
09:50AM	MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? (Zacks)
Dec-24-25 11:22AM	FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug (Zacks)
11:05AM	AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label (Zacks)
09:59AM	Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise (Zacks)
08:55AM	What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' (Zacks)
Dec-23-25 10:45AM	GILD Exercises Option to License Assembly Bio's Herpes Programs (Zacks)
10:35AM	CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies (Zacks)
10:21AM	JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis (Zacks)
03:13AM	AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised) (Zacks)
Dec-22-25 10:25AM	AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use (Zacks)
Dec-19-25 10:10AM	MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab (Zacks)
08:59AM	Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema (Zacks)
07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-18-25 10:51AM	SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag (Zacks)
09:21AM	PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study (Zacks)
Dec-17-25 10:29AM	GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment (Zacks)
09:47AM	RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know (Zacks)
08:43AM	FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug (Zacks)
07:00AM	Landmark Study Shows Combination of Castle Biosciences' DecisionDx-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma (GlobeNewswire)
Dec-16-25 10:43AM	AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Zacks)
10:10AM	KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data (Zacks)
09:55AM	CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike (Zacks)
Dec-15-25 10:27AM	GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU (Zacks)
Dec-12-25 10:08AM	GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea (Zacks)
07:00AM	Systematic Review and Meta-Analysis Confirms TissueCypher Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer (GlobeNewswire)
Dec-11-25 11:03AM	GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer (Zacks)
09:40AM	Are Medical Stocks Lagging Cronos Group (CRON) This Year? (Zacks)
Dec-10-25 09:43AM	TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia (Zacks)
Dec-09-25 10:43AM	KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study (Zacks)
10:24AM	Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date (Zacks)
07:00AM	Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma (GlobeNewswire)
Dec-08-25 08:55AM	Here's Why 'Trend' Investors Would Love Betting on Castle Biosciences (CSTL) (Zacks)
Nov-25-25 10:45AM	SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria (Zacks)
Nov-24-25 10:50AM	FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer (Zacks)
Nov-21-25 08:55AM	Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +6.05%
Nov-20-25 09:14AM	ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal (Zacks)
08:48AM	5 Stocks With Recent Price Strength Amid Wall Street Volatility (Zacks)
Nov-19-25 10:59AM	Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri (Zacks)
Nov-18-25 10:36AM	Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal (Zacks)
Nov-17-25 07:00AM	Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year (GlobeNewswire)
03:49AM	Zacks.com featured highlights include Perimeter Solutions, Interface, Castle Biosciences and Great Lakes Dredge & Dock (Zacks)
Nov-14-25 07:39AM	Forget the Fed, Bet on These 4 Stocks With Increasing Cash Flows (Zacks)
07:00AM	New Data Confirms Performance of DecisionDx-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity (GlobeNewswire)
Nov-12-25 06:02AM	Zacks.com featured highlights include Castle Biosciences, Perimeter Solutions, South Atlantic Bancshares and Astronics (Zacks)
Nov-11-25 07:00AM	Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
01:43AM	4 Stocks With Recent Price Strength to Enhance Your Portfolio (Zacks)
Nov-05-25 12:36PM	Recent Price Trend in Castle Biosciences (CSTL) is Your Friend, Here's Why (Zacks) +6.13%
Nov-04-25 12:02AM	Castle Biosciences Inc (CSTL) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) +21.70%
Nov-03-25 06:05PM	Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Castle Biosciences Reports Third Quarter 2025 Results (GlobeNewswire)
04:05PM	Castle Biosciences Launches AdvanceAD-Tx to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Oct-31-25 09:29AM	Castle Biosciences Inc (CSTL) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +5.33%
03:20AM	Zacks.com featured highlights include RadNet, Mission Produce, Castle Biosciences and FreightCar America (Zacks)
Oct-30-25 12:01PM	Forget Profit, Pick These 4 Stocks With Increasing Cash Flows (Zacks)
07:40AM	Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-28-25 10:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy? (Zacks)
07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-27-25 10:00AM	Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-26-25 03:05PM	New Data at American College of Gastroenterology Annual Meeting Show TissueCypher Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus (GlobeNewswire)
Oct-24-25 04:05AM	New Analysis of 13,560 Patients Demonstrates DecisionDx-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference (GlobeNewswire)

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett's esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Feb 03 '26	Sale	39.91	3,200	127,722	84,515	Feb 05 04:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Feb 04 '26	Sale	37.99	817	31,035	83,698	Feb 05 04:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 20 '26	Sale	40.01	4,017	160,732	87,715	Jan 22 04:15 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 05 '26	Sale	38.09	2,678	102,005	30,852	Jan 07 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 06 '26	Sale	40.10	1,339	53,689	29,513	Jan 07 04:06 PM
Derek Maetzold	Officer	Jan 05 '26	Proposed Sale	39.00	12,051	469,989		Jan 05 05:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 22 '25	Sale	40.35	830	33,490	33,530	Dec 29 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 17 '25	Sale	40.04	509	20,380	34,360	Dec 19 04:06 PM
Oelschlager Kristen M	Chief Operating Officer	Dec 17 '25	Sale	39.31	14,888	585,292	12,323	Dec 19 04:06 PM
Kristen M. Oelschlager	Officer	Dec 17 '25	Proposed Sale	39.05	14,888	581,376		Dec 17 04:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 15 '25	Sale	38.78	19,525	757,099	47,690	Dec 17 04:20 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 16 '25	Sale	38.55	12,821	494,301	34,869	Dec 17 04:20 PM
Derek Maetzold	Officer	Dec 15 '25	Proposed Sale	38.88	33,685	1,309,673		Dec 15 06:21 PM
Juvenal Tobin W	Chief Commercial Officer	Dec 11 '25	Sale	37.48	13,200	494,736	86,825	Dec 15 04:09 PM
Stokes Frank	Chief Financial Officer	Dec 11 '25	Sale	37.45	4,496	168,375	50,326	Dec 15 04:08 PM
TOBIN JUVENAL	Officer	Dec 11 '25	Proposed Sale	37.48	13,200	494,675		Dec 11 04:30 PM
FRANKLIN M. STOKES	Officer	Dec 11 '25	Proposed Sale	37.45	4,496	168,375		Dec 11 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 04 '25	Sale	40.03	1,339	53,600	37,547	Dec 08 04:28 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 02 '25	Sale	39.23	2,678	105,058	38,886	Dec 04 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 26 '25	Sale	40.09	4,258	170,703	41,564	Dec 01 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 25 '25	Sale	40.05	5,115	204,851	45,822	Nov 26 02:58 PM
Derek Maetzold	Officer	Nov 25 '25	Proposed Sale	39.93	10,712	427,730		Nov 25 05:11 PM
TOBIN JUVENAL	Officer	Nov 24 '25	Proposed Sale	37.88	1,301	49,282		Nov 24 04:28 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 20 '25	Option Exercise	3.38	4,693	15,862	89,288	Nov 24 04:24 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 20 '25	Sale	35.58	4,693	166,977	84,595	Nov 24 04:24 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 18 '25	Sale	34.02	2,678	91,106	50,937	Nov 20 04:07 PM
Stokes Frank	Chief Financial Officer	Nov 11 '25	Sale	35.08	5,388	189,011	43,328	Nov 13 04:08 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 11 '25	Sale	35.39	500	17,695	84,027	Nov 13 04:08 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 12 '25	Sale	35.40	200	7,080	83,827	Nov 13 04:08 PM
Oelschlager Kristen M	Chief Operating Officer	Nov 11 '25	Sale	35.10	18,932	664,513	12,323	Nov 13 04:07 PM
Kristen M. Oelschlager	Officer	Nov 11 '25	Proposed Sale	34.74	18,932	657,698		Nov 12 09:32 AM
TOBIN JUVENAL	Officer	Nov 11 '25	Proposed Sale	34.74	5,393	187,353		Nov 12 07:03 AM
FRANKLIN STOKES	Officer	Nov 11 '25	Proposed Sale	34.74	5,388	187,179		Nov 12 06:58 AM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 04 '25	Sale	30.44	6,695	203,782	56,293	Nov 06 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 05 '25	Sale	31.85	2,678	85,297	53,615	Nov 06 04:08 PM
Oelschlager Kristen M	Chief Operating Officer	Oct 31 '25	Sale	25.04	12,678	317,457	27,569	Nov 04 08:56 PM
Derek Maetzold	Officer	Nov 04 '25	Proposed Sale	31.63	13,390	423,526		Nov 04 04:53 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 20 '25	Sale	22.44	1,339	30,047	62,988	Oct 23 09:30 AM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 02 '25	Sale	22.58	1,339	30,235	64,327	Oct 06 04:11 PM
Derek Maetzold	Officer	Oct 02 '25	Proposed Sale	22.23	4,017	89,298		Oct 02 05:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 17 '25	Sale	21.97	1,339	29,419	65,666	Sep 19 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 02 '25	Sale	23.93	1,339	32,042	67,005	Sep 04 04:04 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 27 '25	Sale	22.02	12,677	279,135	141,116	Aug 29 04:04 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 27 '25	Sale	21.69	18,007	390,572	153,793	Aug 29 04:04 PM
Kristen M. Oelschlager	Officer	Aug 27 '25	Proposed Sale	21.35	18,007	384,449		Aug 27 06:15 PM
Kristen M. Oelschlager	Officer	Aug 27 '25	Proposed Sale	21.35	25,355	541,329		Aug 27 04:56 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 15 '25	Sale	20.04	1,339	26,834	68,344	Aug 19 04:04 PM
Derek Maetzold	Officer	Aug 15 '25	Proposed Sale	20.09	4,017	80,702		Aug 15 05:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 13 '25	Sale	19.50	43,019	839,043	69,683	Aug 15 04:14 PM
Derek Maetzold	Officer	Aug 13 '25	Proposed Sale	19.41	43,019	834,999		Aug 13 05:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 08 '25	Option Exercise	0.00	66,991	0	136,674	Aug 12 04:32 PM
Stokes Frank	Chief Financial Officer	Aug 08 '25	Option Exercise	0.00	9,744	0	53,072	Aug 12 04:31 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 08 '25	Option Exercise	0.00	10,640	0	174,604	Aug 12 04:31 PM
Juvenal Tobin W	Chief Commercial Officer	Aug 08 '25	Option Exercise	0.00	10,640	0	88,821	Aug 12 04:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 27 '25	Sale	20.30	17,632	357,930	3,615	Jul 01 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 27 '25	Sale	20.30	4,944	100,363	69,683	Jul 01 04:05 PM
Derek Maetzold	Officer	Jun 27 '25	Proposed Sale	20.35	16,932	344,566		Jun 27 06:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '25	Sale	21.52	4,408	94,851	4,275	Apr 23 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '25	Sale	21.52	1,236	26,596	74,627	Apr 23 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 09 '25	Sale	20.22	3,647	73,739	4,440	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 09 '25	Sale	20.22	1,023	20,684	75,863	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 08 '25	Sale	20.03	761	15,243	4,577	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 08 '25	Sale	20.03	213	4,266	76,886	Apr 10 04:07 PM
Derek Maetzold	Officer	Apr 08 '25	Proposed Sale	18.60	16,932	314,935		Apr 08 04:56 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '25	Sale	20.30	4,408	89,482	4,605	Mar 28 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '25	Sale	20.30	1,236	25,091	77,099	Mar 28 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '25	Sale	20.12	22,639	455,426	80,465	Mar 11 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '25	Sale	20.12	4,408	88,674	4,770	Mar 11 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 10 '25	Sale	19.52	2,130	41,573	78,335	Mar 11 04:07 PM
Derek Maetzold	Officer	Mar 07 '25	Proposed Sale	20.21	34,821	703,732		Mar 07 04:57 PM
Derek Maetzold	Officer	Mar 04 '25	Proposed Sale	22.23	5,687	126,422		Mar 04 05:28 PM
Stokes Frank	Chief Financial Officer	Feb 20 '25	Sale	26.70	8,046	214,828	35,319	Feb 24 04:23 PM

Open in Screener

NTRA

Natera Inc

Feb 17 • 01:45PM ET

210.43

+4.20 2.04 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH TXG EXAS QGEN FLGT TWST MYGN CDNA BNGO

| Held by: VTI VB VBK VXF IBB IWP IWF IWR XBI VHT

Index	-	P/E	-	EPS (ttm)	-2.28	Insider Own	4.81%	Shs Outstand	137.53M	Perf Week	-0.07%
Market Cap	29.11B	Forward P/E	-	EPS next Y	-1.91	Insider Trans	-11.52%	Shs Float	131.67M	Perf Month	-12.45%
Enterprise Value	28.26B	PEG	-	EPS next Q	-0.51	Inst Own	93.59%	Short Float	2.58%	Perf Quarter	4.86%
Income	-309.19M	P/S	13.75	EPS this Y	-56.68%	Inst Trans	-0.26%	Short Ratio	2.66	Perf Half Y	29.08%
Sales	2.12B	P/B	23.11	EPS next Y	20.39%	ROA	-18.12%	Short Interest	3.40M	Perf YTD	-8.15%
Book/sh	9.10	P/C	27.92	EPS next 5Y	46.31%	ROE	-29.02%	52W High	256.36 -17.92%	Perf Year	21.36%
Cash/sh	7.54	P/FCF	274.43	EPS past 3/5Y	33.57% 3.18%	ROIC	-22.79%	52W Low	125.38 67.83%	Perf 3Y	321.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.47% 41.20%	Gross Margin	63.66%	Volatility	3.77% 4.14%	Perf 5Y	83.24%
Dividend TTM	-	EV/Sales	13.35	EPS Y/Y TTM	-28.77%	Oper. Margin	-16.62%	ATR (14)	9.07	Perf 10Y	2818.55%
Dividend Ex-Date	-	Quick Ratio	3.13	Sales Y/Y TTM	38.17%	Profit Margin	-14.61%	RSI (14)	39.92	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	3.27	EPS Q/Q	-150.04%	SMA20	-5.77%	Beta	1.65	Target Price	258.90
Payout	-	Debt/Eq	0.16	Sales Q/Q	34.66%	SMA50	-8.66%	Rel Volume	0.26	Prev Close	206.23
Employees	4434	LT Debt/Eq	0.08	Earnings	Nov 06 AMC	SMA200	13.26%	Avg Volume	1.28M	Price	210.43
IPO	Jul 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-65.93% 15.33%	Trades		Volume	224,418	Change	2.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Citigroup	Buy	$300
Dec-02-25	Resumed	Morgan Stanley	Overweight	$265
Oct-27-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$172
Sep-22-25	Resumed	Wells Fargo	Equal Weight	$175
Mar-13-25	Initiated	RBC Capital Mkts	Outperform	$251
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90

Show Previous Ratings

Today 09:00AM	Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026 (Business Wire)
Feb-12-26 07:27AM	Surgery Partners (SGRY) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Feb-11-26 09:56AM	EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus (Zacks)
Feb-10-26 07:40AM	CVS Health (CVS) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-06-26 06:00AM	Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes (Business Wire)
05:15PM	Loading…
Feb-03-26 05:15PM	InnovAge Holding Corp. (INNV) Q2 Earnings and Revenues Surpass Estimates (Zacks) -9.69%
10:29AM	Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test (Zacks)
Feb-02-26 06:00AM	Natera Submits Signatera CDx PMA to FDA (Business Wire)
Jan-29-26 07:29AM	Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue (Insider Monkey)
Jan-26-26 06:00AM	Prospera Featured in Landmark Interventional Study Advancing Lung Transplant Care (Business Wire)
Jan-25-26 11:38PM	2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds (StockStory)
Jan-23-26 10:53AM	Lack of Natera (NTRA) Exposure Weighs on Mid-Cap Fund Performance (Insider Monkey)
Jan-21-26 06:00AM	Natera Publishes Clinical Validation of Latitude Tissue-Free MRD Test in Colorectal Cancer (Business Wire)
Jan-20-26 06:00AM	Natera's Fetal Focus Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting (Business Wire)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:00AM	Loading…
08:00AM	Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling (Business Wire)
Jan-12-26 10:00AM	Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA (Business Wire)
Jan-11-26 10:48PM	Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth (Business Wire)
Jan-08-26 08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks) -5.83%
Jan-07-26 02:11PM	Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera (CNBC TV)
09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
08:04AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonalds, Moderna, and More (24/7 Wall St.)
08:00AM	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer (Business Wire)
Jan-05-26 07:25PM	Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI (Business Wire)
07:00AM	Natera Launches 21-Gene Fetal Focus Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP Technology (Business Wire)
Dec-31-25 11:56AM	Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study (Insider Monkey)
Dec-30-25 02:16PM	Medical Stock Hovers Near Buy Point After 46% Gain (Investor's Business Daily)
Dec-26-25 03:40PM	Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens (Investor's Business Daily)
Dec-23-25 11:03PM	3 Reasons We're Fans of Natera (NTRA) (StockStory)
Dec-22-25 10:19PM	J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum (Insider Monkey)
08:00AM	Loading…
08:00AM	Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-25 08:00AM	Natera Announces Publication of Signatera Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer (Business Wire)
Dec-12-25 08:00AM	Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer (Business Wire)
Dec-11-25 10:11AM	Crypto Market 2026 Predictions: Which Coins Will 10x and Which Will Crash? (24/7 Wall St.)
10:11AM	Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks (24/7 Wall St.)
Dec-10-25 07:57PM	Phase III PALLAS Study Shows Signatera MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer (Business Wire)
06:15AM	Natera acquires Foresight Diagnostics for up to $450M (MedTech Dive)
Dec-09-25 08:00AM	Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting (Business Wire)
Dec-08-25 04:46AM	Natera purchases Foresight Diagnostics (Medical Device Network)
Dec-05-25 07:00AM	Natera Acquires Foresight Diagnostics (Business Wire)
Dec-03-25 08:00AM	New Signatera Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting (Business Wire)
Dec-02-25 08:00AM	Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera at the San Antonio Breast Cancer Symposium (Business Wire)
Nov-30-25 03:14AM	30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks (Motley Fool)
Nov-24-25 07:00PM	Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know (StockStory)
12:38PM	This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks Hes Buying Now. (24/7 Wall St.)
Nov-21-25 06:55PM	Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know (StockStory)
Nov-20-25 01:25PM	Cathie Wood Targets New Tech Winners, Dumps AMD in Major Shuffle (GuruFocus.com)
Nov-19-25 10:40PM	Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3 (StockStory)
08:00AM	Employees Volunteer Over 1,500 Hours During Natera's Annual Volunteer Month (Business Wire)
Nov-18-25 04:45AM	TD Cowen Lifts Natera (NTRA) Target to $240, Reiterates Buy Rating (Insider Monkey)
Nov-14-25 03:05PM	Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3. ... (GuruFocus.com)
07:58AM	Does Natera (NTRA) Have a Long Runway For Growth? (Insider Monkey)
Nov-12-25 08:00AM	Natera Integrates with Flatiron Health's OncoEMR Platform (Business Wire)
Nov-11-25 11:39PM	1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds (StockStory)
Nov-07-25 09:27AM	NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase (StockStory)
12:03AM	Natera Inc (NTRA) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions (GuruFocus.com)
Nov-06-25 07:30PM	Here's What Key Metrics Tell Us About Natera (NTRA) Q3 Earnings (Zacks)
05:50PM	Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:02PM	Natera (NASDAQ:NTRA) Delivers Impressive Q3 (StockStory)
04:46PM	Natera: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-04-25 10:19PM	Natera (NTRA) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-31-25 07:00AM	Natera Announces Expansion to 20 Genes for its Fetal Focus Single-Gene NIPT (Business Wire)
Oct-30-25 07:00AM	Natera to Report its Third Quarter Results on November 6, 2025 (Business Wire)
Oct-28-25 07:00AM	Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity (Business Wire)
Oct-27-25 06:20AM	Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-20-25 11:31PM	Reflecting On Immuno-Oncology Stocks' Q2 Earnings: Natera (NASDAQ:NTRA) (StockStory)
01:35PM	Why Are Natera (NTRA) Shares Soaring Today (StockStory)
01:05AM	Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients (Business Wire)
Oct-16-25 08:00AM	Natera Named to Fast Company's Next Big Things in Tech List (Business Wire)
Oct-13-25 09:28AM	Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer (Insider Monkey)
08:00AM	Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings (Business Wire)
Oct-12-25 06:10PM	Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium (Business Wire)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Sep-30-25 08:00AM	Natera Announces Publication of Signatera Validation Study in Testicular Cancer (Business Wire)
Sep-29-25 08:00AM	Signatera Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows (Business Wire)
12:36AM	2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds (StockStory)
Sep-24-25 04:05PM	Why Natera (NTRA) Stock Is Down Today (StockStory) -5.16%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
Sep-22-25 09:35AM	Humana initiated, Paycom upgraded: Wall Street's top analyst calls (The Fly)
Sep-12-25 04:01PM	Why Natera (NTRA) Stock Is Trading Lower Today (StockStory)
Sep-10-25 03:11PM	Why Natera (NTRA) Shares Are Falling Today (StockStory)
12:02AM	3 Reasons We're Fans of Natera (NTRA) (StockStory)
Sep-02-25 01:04AM	Natera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomics (Insider Monkey)
Aug-29-25 05:05PM	Health Care Roundup: Market Talk (The Wall Street Journal)
01:46PM	Why Natera (NTRA) Stock Is Down Today (StockStory)
01:04PM	NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims (Benzinga)
08:18AM	Natera Provides Update on Patent Litigation with NeoGenomics (Business Wire)
04:46AM	Nateras Signatera test to be used in Phase III bladder cancer trial (Medical Device Network)
Aug-28-25 03:56PM	Why Natera (NTRA) Stock Is Up Today (StockStory)
08:00AM	Signatera Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer (Business Wire)
Aug-25-25 12:52PM	Natera Shares Rise on the Launch of AI Platform for Precision Oncology (Zacks)
08:00AM	Natera to Present Signatera Data at the IASLC World Conference on Lung Cancer (Business Wire)
Aug-22-25 06:04AM	Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine (Business Wire)
05:00AM	Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation (Business Wire)
12:40AM	1 Healthcare Stock to Own for Decades and 2 We Find Risky (StockStory)
Aug-18-25 12:33PM	Natera pursues ctDNA assay approval after Phase III victory (Clinical Trials Arena)
06:00AM	IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera Strongly Predicting Adjuvant Immunotherapy Benefit (Business Wire)
Aug-15-25 07:15PM	Stanley Druckenmiller's Strategic Moves: Significant Reduction in Coupang Inc. by 3.73% (GuruFocus.com)
Aug-14-25 06:06PM	Liberty All-Star® Growth Fund, Inc. July 2025 Monthly Update (Business Wire)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 02 '26	Sale	231.44	3,000	694,309	139,486	Feb 04 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 03 '26	Sale	230.77	1,639	378,229	137,847	Feb 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Feb 02 '26	Sale	230.72	85,299	19,680,040	127,881	Feb 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Feb 03 '26	Sale	230.77	4,725	1,090,379	123,156	Feb 04 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 03 '26	Sale	227.83	6,939	1,580,926	52,120	Feb 04 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Feb 03 '26	Sale	231.02	3,594	830,279	178,081	Feb 04 09:05 PM
Sheena Jonathan	CO-FOUNDER	Feb 03 '26	Sale	230.77	435	100,384	263,161	Feb 04 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 03 '26	Sale	230.77	1,334	307,845	223,813	Feb 04 09:05 PM
MICHAEL BROPHY	Officer	Feb 03 '26	Proposed Sale	231.10	5,671	1,310,568		Feb 03 04:32 PM
STEVEN L CHAPMAN	Officer	Feb 02 '26	Proposed Sale	230.72	85,299	19,679,799		Feb 02 04:58 PM
SOLOMON MOSHKEVICH	Officer	Feb 02 '26	Proposed Sale	231.44	3,000	694,309		Feb 02 04:12 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 28 '26	Sale	237.66	3,648	866,992	213,180	Jan 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 27 '26	Sale	240.53	2,322	558,514	216,828	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 28 '26	Sale	237.56	2,413	573,221	60,926	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 29 '26	Sale	230.40	1,867	430,156	59,059	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 27 '26	Sale	240.53	784	188,577	63,339	Jan 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 27 '26	Sale	240.53	291	69,995	263,787	Jan 29 08:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 28 '26	Sale	237.66	191	45,394	263,596	Jan 29 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 28 '26	Sale	237.66	1,000	237,662	225,147	Jan 29 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 27 '26	Sale	240.53	886	213,111	226,147	Jan 29 08:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 28 '26	Sale	237.66	1,200	285,195	142,486	Jan 29 08:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 27 '26	Sale	240.53	1,013	243,658	143,686	Jan 29 08:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 28 '26	Sale	237.66	928	220,551	175,540	Jan 29 08:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 27 '26	Sale	240.53	784	188,577	176,468	Jan 29 08:35 PM
MICHAEL BROPHY	Officer	Jan 29 '26	Proposed Sale	235.93	1,867	440,481		Jan 29 04:10 PM
MICHAEL BROPHY	Officer	Jan 28 '26	Proposed Sale	240.34	1,176	282,640		Jan 28 04:19 PM
Sheena Jonathan	CO-FOUNDER	Jan 23 '26	Sale	243.94	1,500	365,914	21,782	Jan 27 08:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 20 '26	Sale	234.74	71,932	16,885,203	217,354	Jan 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 21 '26	Sale	235.00	1,590	373,650	219,150	Jan 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 21 '26	Sale	242.54	37,175	9,016,585	64,123	Jan 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 20 '26	Sale	234.74	23,948	5,621,515	99,776	Jan 22 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 21 '26	Sale	234.46	3,163	741,612	264,078	Jan 22 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jan 20 '26	Sale	234.74	2,981	699,755	267,050	Jan 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 20 '26	Sale	234.74	19,234	4,514,958	226,615	Jan 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 21 '26	Sale	235.00	438	102,930	227,033	Jan 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 20 '26	Sale	234.74	23,205	5,447,105	144,992	Jan 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 21 '26	Sale	235.00	293	68,855	144,699	Jan 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 20 '26	Sale	234.74	17,806	4,179,752	177,591	Jan 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 21 '26	Sale	235.00	339	79,665	177,252	Jan 22 09:05 PM
MICHAEL BROPHY	Officer	Jan 21 '26	Proposed Sale	234.85	36,573	8,589,169		Jan 21 04:54 PM
Sheena Jonathan	CO-FOUNDER	Jan 05 '26	Option Exercise	9.59	39,615	379,908	262,581	Jan 06 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 02 '26	Sale	228.95	2,951	675,621	123,499	Jan 06 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 02 '26	Sale	229.08	3,848	881,482	136,568	Jan 06 09:05 PM
SOLOMON MOSHKEVICH	Officer	Jan 02 '26	Proposed Sale	228.95	2,951	675,621		Jan 02 04:13 PM
STEVEN L CHAPMAN	Officer	Jan 02 '26	Proposed Sale	229.08	3,848	881,482		Jan 02 04:13 PM
Sheena Jonathan	CO-FOUNDER	Dec 19 '25	Sale	225.94	1,500	338,914	22,532	Dec 22 08:05 PM
Sheena Jonathan	Director	Dec 19 '25	Proposed Sale	220.00	4,500	990,000		Dec 19 10:03 AM
Sheena Jonathan	CO-FOUNDER	Dec 17 '25	Sale	227.01	3,070	696,912	222,966	Dec 17 08:35 PM
Sheena Jonathan	Director	Dec 17 '25	Proposed Sale	228.00	9,210	2,099,880		Dec 17 11:44 AM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 12 '25	Option Exercise	9.59	22,376	214,586	126,565	Dec 16 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 12 '25	Sale	230.76	4,692	1,082,714	113,065	Dec 16 09:05 PM
ROSENMAN HERM	Director	Dec 12 '25	Sale	227.42	48,419	11,011,477	20,342	Dec 16 09:05 PM
SOLOMON MOSHKEVICH	Officer	Dec 12 '25	Proposed Sale	230.76	4,692	1,082,714		Dec 12 05:17 PM
Herm Rosenman Trust	Board member	Dec 12 '25	Proposed Sale	233.13	48,419	11,287,921		Dec 12 10:07 AM
Sheena Jonathan	CO-FOUNDER	Dec 09 '25	Option Exercise	9.29	4,436	41,210	227,096	Dec 11 08:35 PM
Chapman Rowan E	Director	Dec 05 '25	Option Exercise	32.15	4,000	128,600	10,143	Dec 09 08:35 PM
Chapman Rowan E	Director	Dec 05 '25	Sale	243.10	4,366	1,061,389	5,777	Dec 09 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Dec 04 '25	Option Exercise	19.68	6,902	135,831	208,601	Dec 08 09:55 PM
ROWAN EMMA CHAPMAN	Director	Dec 05 '25	Proposed Sale	243.10	4,366	1,061,391		Dec 05 07:25 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 01 '25	Sale	238.15	3,000	714,459	109,061	Dec 03 08:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Dec 01 '25	Sale	238.07	4,400	1,047,502	140,416	Dec 03 08:35 PM
STEVEN L CHAPMAN	Officer	Dec 01 '25	Proposed Sale	238.07	4,400	1,047,501		Dec 01 04:10 PM
SOLOMON MOSHKEVICH	Officer	Dec 01 '25	Proposed Sale	238.15	3,000	714,459		Dec 01 04:08 PM
BOTHA ROELOF	Director	Nov 24 '25	Sale	236.12	75,000	17,708,936	1,154,198	Nov 26 05:00 PM
BV369 TRUST	Affiliate	Nov 24 '25	Proposed Sale	236.12	75,000	17,709,000		Nov 24 04:50 PM
Sheena Jonathan	CO-FOUNDER	Nov 20 '25	Sale	225.08	10,000	2,250,816	222,660	Nov 21 08:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 21 '25	Sale	230.01	4,000	920,030	23,282	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Option Exercise	41.17	7,668	315,689	26,027	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 19 '25	Option Exercise	40.93	5,112	209,234	23,471	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Sale	223.08	7,668	1,710,600	18,359	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 19 '25	Sale	215.00	5,112	1,099,088	18,359	Nov 21 08:05 PM
ROY BAYNES	Director	Nov 20 '25	Proposed Sale	223.08	7,668	1,710,600		Nov 20 04:03 PM
Sheena Jonathan	Director	Nov 20 '25	Proposed Sale	225.02	10,000	2,250,186		Nov 20 11:21 AM
ROY BAYNES	Director	Nov 19 '25	Proposed Sale	215.00	5,112	1,099,088		Nov 19 04:04 PM
Sheena Jonathan	CO-FOUNDER	Nov 07 '25	Sale	192.56	3,070	591,159	232,660	Nov 12 08:35 PM
Sheena Jonathan	CO-FOUNDER	Nov 11 '25	Sale	207.96	1,500	311,934	25,282	Nov 12 08:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 04 '25	Sale	200.51	22,900	4,591,674	2,280,852	Nov 04 09:35 PM
Sheena Jonathan	CO-FOUNDER	Nov 03 '25	Sale	200.07	4,000	800,274	26,032	Nov 04 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Nov 03 '25	Sale	198.60	3,000	595,810	112,061	Nov 04 09:35 PM
Marcus Gail Boxer	Director	Nov 03 '25	Sale	198.71	122	24,243	5,762	Nov 04 09:05 PM
MATTHEW RABINOWITZ	Director	Nov 04 '25	Proposed Sale	198.23	22,900	4,539,467		Nov 04 04:33 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 03 '25	Option Exercise	116.02	155,679	18,062,483	305,519	Nov 03 09:40 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 03 '25	Sale	199.96	160,703	32,133,981	144,816	Nov 03 09:40 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 03 '25	Sale	200.00	17,100	3,420,003	2,303,752	Nov 03 09:35 PM
MATTHEW RABINOWITZ	Director	Nov 03 '25	Proposed Sale	198.93	17,100	3,401,703		Nov 03 04:26 PM
SOLOMON MOSHKEVICH	Officer	Nov 03 '25	Proposed Sale	198.60	3,000	595,810		Nov 03 04:07 PM
STEVEN L CHAPMAN	Officer	Nov 03 '25	Proposed Sale	199.96	160,703	32,133,983		Nov 03 04:03 PM
Gail Marcus	Director	Nov 03 '25	Proposed Sale	198.71	122	24,243		Nov 03 01:24 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 28 '25	Sale	191.46	3,680	704,580	149,840	Oct 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 27 '25	Sale	192.32	2,335	449,077	153,520	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 28 '25	Sale	191.16	2,415	461,648	65,993	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 29 '25	Sale	190.64	1,867	355,925	64,126	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 27 '25	Sale	192.32	781	150,205	68,408	Oct 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Oct 27 '25	Sale	192.32	288	55,389	235,921	Oct 29 09:05 PM
Sheena Jonathan	CO-FOUNDER	Oct 28 '25	Sale	191.46	191	36,569	235,730	Oct 29 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 28 '25	Sale	191.46	1,058	202,567	201,699	Oct 29 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 27 '25	Sale	192.32	935	179,823	202,757	Oct 29 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 28 '25	Sale	191.46	1,198	229,371	115,061	Oct 29 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 27 '25	Sale	192.32	1,008	193,863	116,259	Oct 29 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 28 '25	Sale	191.46	928	177,677	150,699	Oct 29 09:05 PM

Open in Screener

EXAS

Exact Sciences Corp

Feb 17 • 01:45PM ET

103.33

+0.09 0.09 %

Healthcare • Diagnostics & Research • USA • NASD

EXAS Exact Sciences Corp daily Stock Chart

Peers: ILMN GH NTRA TXG DGX FLGT BIO QDEL MYGN CSTM

| Held by: VTI VB VBK VXF XBI FBT IWR VHT SCHM IWD

Index	-	P/E	-	EPS (ttm)	-1.10	Insider Own	1.93%	Shs Outstand	190.80M	Perf Week	0.01%
Market Cap	19.72B	Forward P/E	88.50	EPS next Y	1.17	Insider Trans	-0.70%	Shs Float	187.13M	Perf Month	0.97%
Enterprise Value	21.29B	PEG	-	EPS next Q	-0.20	Inst Own	88.11%	Short Float	3.55%	Perf Quarter	52.52%
Income	-207.95M	P/S	6.07	EPS this Y	122.15%	Inst Trans	-12.07%	Short Ratio	1.27	Perf Half Y	126.60%
Sales	3.25B	P/B	8.21	EPS next Y	379.20%	ROA	-3.39%	Short Interest	6.65M	Perf YTD	1.74%
Book/sh	12.58	P/C	20.44	EPS next 5Y	-	ROE	-8.66%	52W High	103.54 -0.20%	Perf Year	109.55%
Cash/sh	5.06	P/FCF	55.26	EPS past 3/5Y	32.20% 27.36%	ROIC	-4.25%	52W Low	38.81 166.23%	Perf 3Y	62.77%
Dividend Est.	-	EV/EBITDA	323.01	Sales past 3/5Y	15.92% 16.84%	Gross Margin	69.69%	Volatility	0.25% 0.33%	Perf 5Y	-26.71%
Dividend TTM	-	EV/Sales	6.56	EPS Y/Y TTM	-353.69%	Oper. Margin	-4.79%	ATR (14)	0.40	Perf 10Y	1463.23%
Dividend Ex-Date	-	Quick Ratio	2.17	Sales Y/Y TTM	17.69%	Profit Margin	-6.40%	RSI (14)	74.39	Recom	2.88
Dividend Gr. 3/5Y	- -	Current Ratio	2.43	EPS Q/Q	90.29%	SMA20	0.60%	Beta	1.41	Target Price	104.00
Payout	-	Debt/Eq	1.06	Sales Q/Q	23.12%	SMA50	1.20%	Rel Volume	0.32	Prev Close	103.24
Employees	7200	LT Debt/Eq	1.04	Earnings	Feb 13 AMC	SMA200	50.40%	Avg Volume	5.23M	Price	103.33
IPO	Jan 31, 2001	Option/Short	Yes / Yes	EPS/Sales Surpr.	-317.05% 2.03%	Trades		Volume	1,114,164	Change	0.09%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-20-26	Downgrade	Mizuho	Outperform → Neutral	$105
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line	$105
Apr-10-25	Initiated	Mizuho	Outperform	$60
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform	$52
Jan-23-25	Initiated	Barclays	Overweight	$70
Aug-28-24	Initiated	Wells Fargo	Overweight	$75
Jun-27-24	Initiated	Scotiabank	Sector Outperform	$70
Jun-03-24	Resumed	Jefferies	Buy	$75
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy	$91
Dec-14-23	Initiated	Guggenheim	Buy	$90
Dec-13-23	Initiated	Wolfe Research	Outperform	$95
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$90
Sep-28-23	Initiated	Bernstein	Outperform	$83
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy	$55 → $85
May-05-23	Initiated	UBS	Neutral	$73
Mar-09-23	Upgrade	Citigroup	Neutral → Buy	$70 → $90
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral	$50 → $70
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold	$60 → $35

Show Previous Ratings

Feb-16-26 10:57PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
11:40AM	CSLLY vs. EXAS: Which Stock Is the Better Value Option? (Zacks)
Feb-13-26 05:15PM	Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Exact Sciences: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results (Business Wire)
01:04PM	Loading…
Feb-12-26 01:04PM	Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next? (24/7 Wall St.)
Feb-09-26 11:01AM	Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. (Barrons.com)
Feb-08-26 11:04PM	Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Feb-06-26 05:41PM	Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. (Barrons.com)
Feb-03-26 02:32PM	Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests (Business Wire)
09:03AM	Oncotype DX Breast Recurrence Score Test Surpasses 2 Million Patients Worldwide (Business Wire)
08:30AM	Multiple Tailwinds Lifted Exact Sciences Corporation (EXAS) in 2025 (Insider Monkey)
Feb-02-26 12:05PM	The Best Dividend King to Buy With $150 (Motley Fool)
Jan-28-26 06:46AM	Medtech M&A took off in the second half of 2025: report (MedTech Dive)
Jan-27-26 11:40AM	EXEL vs. EXAS: Which Stock Is the Better Value Option? (Zacks)
07:46AM	Loading…
07:46AM	Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement (Insider Monkey)
Jan-26-26 06:40AM	3 Reasons to Buy This Dividend King After Its Steep Sell-Off (Motley Fool)
Jan-22-26 04:02PM	Abbott Falls Most in Nearly 24 Years on Formula Pricing Stumble (Bloomberg)
04:01PM	Abbott Laboratories (ABT) Q4 2025 Earnings Call Highlights: Navigating Market Challenges with ... (GuruFocus.com)
02:16PM	Alkermes Stock Earns Technical Rating Upgrade (Investor's Business Daily)
09:48AM	Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints (Benzinga)
08:53AM	Abbott Tumbles On Disappointing Fourth Quarter As Exact Closing Looms (Investor's Business Daily)
Jan-20-26 08:47AM	Exact Sciences (EXAS) Rose Following the Acquisition Announcement by Abbott (Insider Monkey)
07:55AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Chevron, Dominos Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More (24/7 Wall St.)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 07:51AM	Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold? (Zacks)
Jan-09-26 02:24PM	Clinical Labs Hope to Head Off Looming Medicare Cuts (Barrons.com)
Jan-08-26 04:30PM	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 (Business Wire)
12:48PM	Halper Sadeh LLC Encourages FRGE, EXAS, CIVI, KVUE Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
12:21PM	CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois (Zacks)
12:31PM	Loading…
Jan-07-26 12:31PM	Select Medical Expands Rehab Footprint Through Vibra Healthcare JV (Zacks)
11:52AM	ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies (Zacks)
11:49AM	JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus (Zacks)
Jan-06-26 11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks)
11:00AM	Halper Sadeh LLC Encourages EXAS, SOAR, BTBD Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Jan-04-26 11:32PM	1 High-Flying Stock on Our Watchlist and 2 We Question (StockStory)
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-30-25 07:32AM	Should You Continue to Hold EXAS Stock in Your Portfolio Now? (Zacks)
07:32AM	How Tempus AI Is Building Scale While Near-Term Risks Persist (Zacks)
Dec-26-25 01:48PM	Moderna Stock Sees Healthy Relative Strength Rating (Investor's Business Daily)
Dec-16-25 02:09PM	Pacira BioSciences Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Dec-15-25 02:59PM	Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Dec-11-25 05:30PM	Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect MRD Test in Early Triple-Negative Breast Cancer at SABCS (Business Wire)
Dec-10-25 11:35PM	1 Healthcare Stock for Long-Term Investors and 2 We Avoid (StockStory)
Dec-08-25 01:35AM	Freenome inks deals to list stock and raise $330M (MedTech Dive)
Dec-05-25 09:41AM	Tempus AI: Revenue Mix and 2026 Growth Outlook Explained (Zacks)
Dec-03-25 11:30AM	Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report? (Zacks)
Dec-02-25 04:54AM	Here's Why Grail Soared, Again, in November (Motley Fool)
Dec-01-25 12:33PM	Cathie Wood dumps $8.46 million in software giant (TheStreet)
Nov-30-25 02:05AM	This Top Dividend King Just Became an Even Better Buy (Motley Fool)
Nov-28-25 12:41PM	Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-25-25 09:36AM	Brinker upgraded, Coinbase downgraded: Wall Street's top analyst calls (The Fly)
09:17AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More (24/7 Wall St.)
01:33AM	Halper Sadeh LLC Encourages GDOT, BLFY, EXAS Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-24-25 04:35PM	Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium (Business Wire)
09:41AM	Booking, Carvana upgraded: Wall Street's top analyst calls (The Fly)
09:20AM	Here are Mondays Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More (24/7 Wall St.)
Nov-23-25 10:30PM	Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks (StockStory)
Nov-21-25 09:10AM	Here Are Fridays Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More (24/7 Wall St.)
07:32AM	Health Care Roundup: Market Talk (The Wall Street Journal)
06:30AM	Abbott Breaks into Lucrative Cancer Screening Market with $21 Billion Exact Sciences Purchase (The Daily Upside)
04:50AM	Abbott to acquire all outstanding shares in Exact Sciences (Medical Device Network)
03:35AM	Stock Market Today: Dow Futures Inch Up; Bitcoin Slides; VIX Jumps (The Wall Street Journal)
Nov-20-25 07:50PM	Halper Sadeh LLC Encourages CIVI, JAMF, EXAS Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire) +16.81%
07:43PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
06:29PM	Why the Stock Price of This Cancer Screening Company Soared 17% Thursday (Investopedia)
05:06PM	Health Care Roundup: Market Talk (The Wall Street Journal)
05:05PM	Stocks to Watch Thursday Recap: Walmart, Nvidia, Cracker Barrel, Regeneron (The Wall Street Journal)
04:44PM	Biggest Stock Movers Today, Nov. 20: PACS, BBWI, & More (Motley Fool)
04:23PM	These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More (Barrons.com)
04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire)
04:14PM	Exact Sciences Catapults On $23 Billion Abbott Labs Buyout (Investor's Business Daily)
03:31PM	Why Exact Sciences Rallied Over 50% This Week (Motley Fool)
03:08PM	Abbott Laboratories announces $21 billion deal to buy Cologuard-maker Exact Sciences (Chicago Tribune)
03:03PM	Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here? (Barchart)
03:01PM	Why Exact Sciences Stock Surged Today (Motley Fool)
02:47PM	These Stocks Are Moving the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More (Barrons.com)
01:36PM	Stocks to Watch Thursday: Walmart, Nvidia, Cracker Barrel, Regeneron (The Wall Street Journal)
01:02PM	Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and More (Investopedia)
12:01PM	Madison's Exact Sciences' $23 billion sale is tied to its Cologuard cancer test. What to know (Milwaukee Journal Sentinel)
11:51AM	Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion (Barrons.com)
11:32AM	What to know about Exact Sciences. The Madison company was sold to Abbot for $23 billion. (Milwaukee Journal Sentinel)
10:21AM	Exact Sciences Soars As Abbott Unveils $21 Billion Buyout (GuruFocus.com)
09:41AM	Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences (The Wall Street Journal)
09:31AM	Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences (Financial Times)
09:26AM	Abbott to buy Exact Sciences for $21B, Verizon to cut 13K jobs (Yahoo Finance Video)
08:43AM	Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test (MarketWatch)
08:09AM	Exact Sciences stock jumps after Abbott confirms acquisition (Investing.com)
07:46AM	Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. (Barrons.com)
07:46AM	Abbott to Acquire Exact Sciences for $21 Billion (The Wall Street Journal)
07:30AM	Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments (PR Newswire)
06:27AM	Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports (Insider Monkey)
Nov-19-25 07:21PM	Why Exact Sciences Stock Blasted Nearly 24% Higher Today (Motley Fool) +23.68%
04:57PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
04:31PM	Exact Sciences Catapults, Breaking Out, On Rumored Abbott Laboratories Buyout (Investor's Business Daily)
04:27PM	Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories (Barrons.com)
02:36PM	Exact Sciences shares soar on report Abbott is nearing deal for the company (Investing.com)
11:19AM	Stock Market Today: Fed Minutes Weigh on U.S. Equities As Traders Await News (TheStreet)
06:22AM	Freenome and Roche partner on cancer screening technology for ex-US markets (Medical Device Network)
Nov-17-25 01:13PM	Molina Secures Deal From AHCA to Serve Florida's Medicaid Members (Zacks)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORVILLE JACOB A	EVP, GM, Screening	Dec 23 '25	Option Exercise	0.00	73,080	0	69,511	Dec 30 04:30 PM
Baranick Brian	EVP, GM, Precision Oncology	Dec 23 '25	Option Exercise	0.00	73,080	0	66,487	Dec 30 04:30 PM
Condella Sarah	EVP, Human Resources	Dec 23 '25	Option Exercise	0.00	47,208	0	118,059	Dec 30 04:30 PM
Herriott James	SVP, General Counsel & Sec	Dec 23 '25	Option Exercise	0.00	33,780	0	32,934	Dec 30 04:30 PM
Bloomer Aaron	EVP, Chief Financial Officer	Dec 23 '25	Option Exercise	0.00	63,099	0	59,571	Dec 30 04:30 PM
ORVILLE JACOB A	EVP, GM, Screening	Nov 19 '25	Sale	75.00	5,000	375,000	23,237	Nov 21 05:30 PM
Herriott James	SVP, General Counsel & Sec	Nov 19 '25	Sale	70.00	1,000	70,000	11,585	Nov 21 05:30 PM
ORVILLE JACOB A	Officer	Nov 19 '25	Proposed Sale	75.00	5,000	375,000		Nov 19 03:11 PM
Herriott James	Officer	Nov 19 '25	Proposed Sale	70.00	1,000	70,000		Nov 19 12:04 PM
Herriott James	SVP, General Counsel & Sec	Nov 04 '25	Sale	70.08	1,500	105,120	12,585	Nov 06 05:29 PM
Baranick Brian	EVP, GM, Precision Oncology	Nov 04 '25	Sale	70.08	2,858	200,289	22,368	Nov 06 05:29 PM
Baranick Brian	Officer	Nov 04 '25	Proposed Sale	70.08	2,858	200,289		Nov 04 10:25 AM
Herriott James	Officer	Nov 04 '25	Proposed Sale	70.08	1,500	105,120		Nov 04 10:22 AM
Zanotti Katherine S	Director	Oct 24 '25	Sale	65.00	12,000	780,000	60,759	Oct 27 08:35 PM
Zanotti Katherine S	Director	Oct 24 '25	Proposed Sale	65.00	12,000	780,000		Oct 24 11:08 AM
Herriott James	SVP, General Counsel & Sec	Oct 09 '25	Sale	60.00	1,500	90,000	14,085	Oct 10 05:27 PM
Doyle James Edward	Director	Oct 09 '25	Sale	60.00	2,000	120,000	57,962	Oct 10 05:25 PM
Herriott James	Officer	Oct 09 '25	Proposed Sale	60.00	1,500	90,000		Oct 09 11:23 AM
Doyle James Edward	Director	Oct 09 '25	Proposed Sale	60.00	2,000	120,000		Oct 09 11:18 AM
Doyle James Edward	Director	Aug 13 '25	Sale	42.02	1,485	62,400	59,962	Aug 14 04:30 PM
Doyle James Edward	Director	Aug 13 '25	Proposed Sale	42.02	1,485	62,400		Aug 13 10:09 AM
ORVILLE JACOB A	EVP, GM, Screening	Aug 05 '25	Option Exercise	0.00	5,350	0	30,752	Aug 07 05:30 PM
Baranick Brian	EVP, GM, Precision Oncology	Aug 05 '25	Option Exercise	0.00	5,350	0	27,943	Aug 07 05:30 PM
Sebelius Kathleen	Former Director	Jul 16 '25	Proposed Sale	53.11	8,164	433,605		Jul 16 04:22 PM
Zanotti Katherine S	Director	Jun 13 '25	Sale	53.20	3,207	170,612	72,759	Jun 16 05:30 PM
Zanotti Katherine S	Director	Jun 13 '25	Proposed Sale	53.20	3,207	170,612		Jun 13 09:50 AM
Bloomer Aaron	EVP, Chief Financial Officer	Apr 15 '25	Option Exercise	0.00	24,460	0	19,340	Apr 17 04:30 PM
Conroy Kevin T	President and CEO	Mar 07 '25	Option Exercise	22.38	66,723	1,493,261	1,203,269	Mar 10 05:00 PM
Herriott James	SVP, General Counsel & Sec	Feb 28 '25	Option Exercise	0.00	4,265	0	16,339	Mar 04 04:48 PM
Conroy Kevin T	President and CEO	Feb 28 '25	Option Exercise	0.00	40,310	0	1,146,965	Mar 04 04:47 PM
Baranick Brian	EVP, GM, Precision Oncology	Feb 28 '25	Option Exercise	0.00	9,673	0	25,106	Mar 04 04:44 PM
ORVILLE JACOB A	EVP, GM, Screening	Feb 28 '25	Option Exercise	0.00	9,673	0	27,728	Mar 04 04:40 PM
Condella Sarah	EVP, Human Resources	Feb 28 '25	Option Exercise	0.00	7,738	0	84,399	Mar 04 04:37 PM
Condella Sarah	EVP, Human Resources	Feb 25 '25	Option Exercise	0.00	3,954	0	80,297	Feb 26 08:00 PM
Baranick Brian	EVP, GM, Precision Oncology	Feb 25 '25	Option Exercise	0.00	3,954	0	19,841	Feb 26 08:00 PM
Herriott James	SVP, General Counsel & Sec	Feb 25 '25	Option Exercise	0.00	1,647	0	13,738	Feb 26 08:00 PM
ORVILLE JACOB A	EVP, GM, Screening	Feb 25 '25	Option Exercise	0.00	3,954	0	22,136	Feb 26 08:00 PM
Conroy Kevin T	President and CEO	Feb 25 '25	Option Exercise	0.00	13,180	0	1,121,378	Feb 26 08:00 PM
Conroy Kevin T	President and CEO	Feb 19 '25	Option Exercise	0.00	10,374	0	1,084,565	Feb 21 04:30 PM
COWARD D SCOTT	Director	Feb 19 '25	Option Exercise	0.00	2,248	0	52,831	Feb 21 04:30 PM
ORVILLE JACOB A	EVP, GM, Screening	Feb 19 '25	Option Exercise	0.00	2,248	0	16,688	Feb 21 04:30 PM
Baranick Brian	EVP, GM, Precision Oncology	Feb 19 '25	Option Exercise	0.00	1,729	0	14,487	Feb 21 04:30 PM
Condella Sarah	EVP, Human Resources	Feb 19 '25	Option Exercise	0.00	2,248	0	74,859	Feb 21 04:30 PM
Herriott James	SVP, General Counsel & Sec	Feb 19 '25	Option Exercise	0.00	865	0	10,731	Feb 21 04:30 PM

Open in Screener

LH

Labcorp Holdings Inc

Feb 17 • 01:45PM ET

274.96

-7.67 -2.71 %

Healthcare • Diagnostics & Research • USA • NYSE

LH Labcorp Holdings Inc daily Stock Chart

Peers: DGX NEO OPK ICLR QDEL AVTR

| Held by: VTI VOO VO IVV SPY VTV RSP XLV VOE IWR

Index	S&P 500	P/E	27.00	EPS (ttm)	10.18	Insider Own	0.32%	Shs Outstand	83.00M	Perf Week	0.35%
Market Cap	22.79B	Forward P/E	14.42	EPS next Y	19.07	Insider Trans	-6.45%	Shs Float	82.61M	Perf Month	2.26%
Enterprise Value	28.74B	PEG	1.83	EPS next Q	4.10	Inst Own	98.48%	Short Float	3.86%	Perf Quarter	2.65%
Income	855.20M	P/S	1.66	EPS this Y	6.54%	Inst Trans	-2.82%	Short Ratio	4.41	Perf Half Y	1.69%
Sales	13.77B	P/B	2.62	EPS next Y	8.88%	ROA	4.64%	Short Interest	3.19M	Perf YTD	9.60%
Book/sh	104.78	P/C	38.11	EPS next 5Y	7.89%	ROE	10.14%	52W High	293.72 -6.39%	Perf Year	11.55%
Cash/sh	7.21	P/FCF	16.51	EPS past 3/5Y	-28.70% 1.13%	ROIC	5.88%	52W Low	209.38 31.32%	Perf 3Y	24.90%
Dividend Est.	2.88 (1.05%)	EV/EBITDA	14.06	Sales past 3/5Y	-6.90% 2.40%	Gross Margin	26.43%	Volatility	2.99% 2.37%	Perf 5Y	31.74%
Dividend TTM	2.88 (1.05%)	EV/Sales	2.09	EPS Y/Y TTM	97.24%	Oper. Margin	9.92%	ATR (14)	7.74	Perf 10Y	202.52%
Dividend Ex-Date	Feb 27, 2026	Quick Ratio	1.35	Sales Y/Y TTM	8.28%	Profit Margin	6.21%	RSI (14)	52.69	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.55	EPS Q/Q	55.52%	SMA20	0.29%	Beta	1.01	Target Price	306.42
Payout	32.58%	Debt/Eq	0.75	Sales Q/Q	8.58%	SMA50	4.17%	Rel Volume	1.72	Prev Close	282.63
Employees	70000	LT Debt/Eq	0.67	Earnings	Feb 17 BMO	SMA200	4.15%	Avg Volume	724.11K	Price	274.96
IPO	Jul 07, 1988	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.13% -1.20%	Trades		Volume	833,814	Change	-2.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Downgrade	HSBC Securities	Buy → Hold	$260
Apr-02-25	Initiated	Redburn Atlantic	Buy	$276
Mar-04-25	Upgrade	Citigroup	Neutral → Buy	$250 → $300
Jan-07-25	Upgrade	Evercore ISI	In-line → Outperform	$260 → $265
Dec-10-24	Resumed	Jefferies	Buy	$265 → $275
Oct-30-24	Upgrade	HSBC Securities	Hold → Buy
Oct-01-24	Initiated	Piper Sandler	Neutral	$235
Mar-25-24	Upgrade	Argus	Hold → Buy	$250
Feb-26-24	Initiated	Leerink Partners	Outperform	$260
Feb-09-24	Initiated	Evercore ISI	In-line	$240
Jan-03-24	Initiated	Barclays	Equal Weight	$222
Sep-06-23	Initiated	HSBC Securities	Hold	$210
Dec-12-22	Downgrade	Citigroup	Buy → Neutral	$275 → $250
Sep-19-22	Downgrade	Argus	Buy → Hold
Aug-22-22	Resumed	Morgan Stanley	Overweight	$300
Jan-28-22	Downgrade	Deutsche Bank	Buy → Hold	$330 → $294
Jan-11-21	Upgrade	Argus	Hold → Buy	$245
Jan-11-21	Downgrade	Wolfe Research	Peer Perform → Underperform
Jan-08-21	Downgrade	Wolfe Research	Outperform → Peer Perform
Jul-14-20	Upgrade	BofA Securities	Neutral → Buy	$194 → $220

Show Previous Ratings

Today 01:46PM	Labcorp Q4 Earnings Call Highlights (MarketBeat)
11:11AM	Pre-Markets in Red to Start Holiday Shortened Week (Zacks)
10:35AM	Pre-Markets Begins Shorter Week Slowly (Zacks)
10:07AM	Labcorp Q4 Earnings Beat, Revenues Miss, Stock Down in Pre-Market (Zacks)
09:30AM	Labcorp (LH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:00AM	Loading…
08:00AM	Labcorp Holdings (LH) Q4 Earnings Surpass Estimates (Zacks)
07:09AM	Labcorp: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Labcorp (NYSE:LH) Misses Q4 CY2025 Sales Expectations (StockStory)
06:50AM	Labcorp Announces 2025 Fourth Quarter and Full Year Results (PR Newswire)
Feb-15-26 10:07PM	Labcorp (LH) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-13-26 08:29PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Feb-11-26 12:10PM	Will Labcorp (LH) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:00AM	Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:15AM	Stay Ahead of the Game With Labcorp (LH) Q4 Earnings: Wall Street's Insights on Key Metrics (Zacks)
07:00AM	Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care (PR Newswire)
09:20PM	Loading…
Feb-10-26 09:20PM	Labcorp closes takeover of Empire City assets to fuel New York expansion (MedTech Dive)
08:57AM	Labcorp's Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Feb-09-26 01:54PM	Analyst Report: Labcorp Holdings Inc. (Morningstar Research)
08:30AM	Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors (PR Newswire)
Feb-05-26 07:38PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Feb-03-26 08:10AM	Investor Concerns Impacted Labcorp (LH) in Q4 (Insider Monkey)
Jan-26-26 09:40AM	How TEM Is Capitalizing on AI-Driven Pathology Market Growth (Zacks)
Jan-21-26 08:30AM	Sorry, 'Dr. Google.' ChatGPT and Claude are now getting into the business of providing health advice. (MarketWatch)
Jan-15-26 04:34PM	These charts show the stock market giving investors a lot to like - for now - as the S&P 500 nears 7,000 (MarketWatch)
04:15PM	Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026 (PR Newswire)
Jan-14-26 06:50AM	Labcorp Declares Quarterly Dividend (PR Newswire)
Jan-13-26 07:00AM	Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk (PR Newswire)
Jan-09-26 02:24PM	Clinical Labs Hope to Head Off Looming Medicare Cuts (Barrons.com)
08:09AM	Labcorps Quarterly Earnings Preview: What You Need to Know (Barchart)
06:03AM	NAMSA acquires Labcorps medical device testing assets (Medical Device Network)
09:00AM	Loading…
Jan-08-26 09:00AM	Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs (Business Wire)
08:30AM	NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp (PR Newswire)
Jan-06-26 08:12AM	Should Labcorp Stock Stay in Your Portfolio Right Now? (Zacks)
Dec-30-25 04:15PM	Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 09:40AM	Here's Why Labcorp Holdings (LH) is a Strong Value Stock (Zacks)
07:58AM	HOLX vs. LH: Which MedTech Stock Is the Stronger Investment Now? (Zacks)
Dec-18-25 09:55AM	Will Strength in Biotechnology Unit Continue to Drive Danaher's Growth? (Zacks)
Dec-16-25 05:24AM	Is Charles River Laboratories Stock Underperforming the Dow? (Barchart)
Dec-15-25 09:00AM	Is the Options Market Predicting a Spike in Labcorp Holdings Stock? (Zacks)
Dec-12-25 09:19AM	How Is Labcorp Holdings' Stock Performance Compared to Other Healthcare Stocks? (Barchart)
Dec-11-25 07:17PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Dec-10-25 11:34PM	3 Profitable Stocks That Fall Short (StockStory)
08:19PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Dec-09-25 11:38AM	Community Health Systems Stock Falls 7% Amid Debt & Other Pressures (Zacks)
Dec-07-25 11:04PM	3 Reasons to Avoid LH and 1 Stock to Buy Instead (StockStory)
Dec-04-25 02:17AM	CHS sells lab assets to Labcorp for $194M (Healthcare Dive)
Dec-03-25 11:30AM	Why Is Pediatrix Medical Group (MD) Up 11.1% Since Last Earnings Report? (Zacks)
Dec-02-25 04:15PM	Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp (Business Wire)
07:53AM	Should You Continue to Hold LH Stock in Your Portfolio? (Zacks)
Nov-28-25 11:30AM	Why Is CVS Health (CVS) Up 4.1% Since Last Earnings Report? (Zacks)
Nov-27-25 11:30AM	Labcorp (LH) Up 8.1% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-25-25 09:40AM	Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term (Zacks)
Nov-24-25 06:46PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
08:30AM	Labcorp Appoints Victor Bulto to Board of Directors (PR Newswire)
Nov-21-25 08:11AM	LH Shares Gain Following Publication of New Plasma Detect MRD Data (Zacks)
06:49AM	Labcorp Holdings Stock: Analyst Estimates & Ratings (Barchart)
Nov-19-25 07:04AM	Labcorp Plasma Detect Clinical Studies Featured in Nature Medicine and Clinical Cancer Research (PR Newswire)
Nov-14-25 06:16AM	Labcorp inks deal to buy Parkview Health outreach laboratory assets (MedTech Dive)
Nov-13-25 10:56PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Nov-11-25 10:35PM	Q3 Earnings Highs And Lows: Labcorp (NYSE:LH) Vs The Rest Of The Testing & Diagnostics Services Stocks (StockStory)
Nov-06-25 05:50PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Nov-05-25 07:32PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Nov-04-25 12:36AM	Labcorp's Q3 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Oct-31-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Oct-30-25 03:14PM	Labcorp Holdings Inc (LH) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Oct-29-25 01:32AM	LH Q3 Deep Dive: Labcorp Sees Diagnostic Growth, Eyes Specialty Testing and Efficiency Initiatives (StockStory)
Oct-28-25 02:42PM	Analyst Report: Labcorp Holdings Inc. (Morningstar Research) -5.79%
12:11PM	Why Labcorp (LH) Stock Is Falling Today (StockStory)
10:01AM	LH Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:45AM	Here's Why Labcorp Holdings (LH) is a Strong Growth Stock (Zacks)
09:30AM	Labcorp (LH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:42AM	Labcorp (NYSE:LH) Reports Q3 In Line With Expectations (StockStory)
08:00AM	Labcorp Holdings (LH) Q3 Earnings Beat Estimates (Zacks)
06:57AM	Labcorp: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	Labcorp Announces 2025 Third Quarter Results (PR Newswire)
Oct-27-25 06:57PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Oct-26-25 11:11PM	Labcorp (LH) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 06:43PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Oct-23-25 07:00AM	Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings (PR Newswire)
Oct-21-25 10:00AM	Labcorp Holdings (LH) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
09:15AM	Labcorp Holdings Inc. (LH) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-20-25 04:28PM	Top Research Reports for AstraZeneca, RTX & Applied Materials (Zacks)
11:40AM	LH vs. DHR: Which Stock Is the Better Value Option? (Zacks)
Oct-15-25 09:15AM	CVS Health Corporation (CVS) Hits Fresh High: Is There Still Room to Run? (Zacks)
08:40AM	Labcorp Gears Up to Report Q3 Earnings: What's in Store for the Stock? (Zacks)
Oct-14-25 09:50AM	Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term (Zacks)
Oct-10-25 11:50AM	3 Medical Service Industry Stocks Poised to Counter Workforce Issues (Zacks)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Oct-09-25 12:00PM	Labcorp (LH) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
10:54AM	Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell? (Zacks)
09:45AM	Why Labcorp Holdings (LH) is a Top Growth Stock for the Long-Term (Zacks)
Oct-08-25 04:15PM	Labcorp Declares Quarterly Dividend (PR Newswire)
06:15AM	Labcorp Holdings Q3 2025 Earnings: What to Expect (Barchart)
Oct-04-25 08:30AM	Labcorp price target raised to $305 from $300 at Evercore ISI (TipRanks)
Sep-30-25 07:00AM	Labcorp Announces Collaboration with Roche to Advance Digital Pathology Capabilities (PR Newswire)
Sep-25-25 04:15PM	Labcorp to Announce Third Quarter Financial Results on October 28, 2025 (PR Newswire)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Sep-24-25 09:15AM	Labcorp Holdings Inc. (LH) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-23-25 08:22AM	Reasons to Add Labcorp Stock to Your Portfolio Right Now (Zacks)
Sep-22-25 10:33AM	Labcorp Holdings Stock: Is LH Outperforming the Healthcare Sector? (Barchart)

Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schechter Adam H	President & CEO	Feb 11 '26	Sale	284.38	5,273	1,499,536	87,343	Feb 13 01:13 PM
Meltzer Jonathan C	EVP, Operations	Feb 12 '26	Sale	290.42	87	25,267	2,782	Feb 13 01:11 PM
Meltzer Jonathan C	EVP, Operations	Feb 10 '26	Sale	276.79	91	25,188	2,696	Feb 12 03:44 PM
Meltzer Jonathan C	Officer	Feb 12 '26	Proposed Sale	290.42	87	25,267		Feb 12 09:49 AM
Schechter Adam H	Officer	Feb 11 '26	Proposed Sale	284.38	5,273	1,499,536		Feb 11 12:59 PM
Meltzer Jonathan C	EVP, Operations	Feb 09 '26	Sale	275.53	88	24,247	2,869	Feb 10 03:04 PM
Meltzer Jonathan C	Officer	Feb 10 '26	Proposed Sale	276.79	91	25,188		Feb 10 10:30 AM
Meltzer Jonathan C	Officer	Feb 09 '26	Proposed Sale	275.53	88	24,247		Feb 09 01:30 PM
Schechter Adam H	President & CEO	Nov 11 '25	Sale	262.75	5,745	1,509,499	87,574	Nov 13 08:47 AM
Schechter Adam H	Officer	Nov 11 '25	Proposed Sale	262.75	5,745	1,509,499		Nov 12 06:54 AM
Parham Richelle P	Director	Oct 31 '25	Sale	254.28	7,009	1,782,273	2,469	Nov 04 10:28 AM
Parham Richelle P	Director	Oct 31 '25	Proposed Sale	254.28	7,009	1,782,273		Oct 31 03:16 PM
van der Vaart Sandra D	EVP, Chief Legal Officer	Aug 13 '25	Option Exercise	131.43	3,903	512,971	6,177	Aug 15 10:55 AM
van der Vaart Sandra D	EVP, Chief Legal Officer	Aug 13 '25	Sale	271.42	3,903	1,059,371	2,274	Aug 15 10:55 AM
van der Vaart Sandra D	Officer	Aug 13 '25	Proposed Sale	271.42	3,903	1,059,371		Aug 13 12:49 PM
Schechter Adam H	President & CEO	Aug 11 '25	Sale	266.78	5,643	1,505,440	93,319	Aug 13 12:29 PM
Schechter Adam H	Officer	Aug 11 '25	Proposed Sale	266.78	5,643	1,505,440		Aug 11 09:50 AM
Gilliland Dwight Gary	Director	Jul 30 '25	Sale	264.95	2,000	529,900	6,656	Aug 01 08:44 AM
Wilkinson Peter J	SVP, Chief Accounting Officer	Jul 29 '25	Sale	261.02	202	52,727	1,852	Jul 31 08:38 AM
Gilliland Dwight Gary	Director	Jul 30 '25	Proposed Sale	264.95	2,000	529,900		Jul 30 04:45 PM
ANDERSON KERRII B	Director	Jul 24 '25	Sale	280.00	3,500	980,000	8,666	Jul 28 03:59 PM
ANDERSON KERRII B	Director	Jul 24 '25	Sale	280.00	3,500	980,000	8,666	Jul 28 03:59 PM
KERRII ANDERSON	Director	Jul 24 '25	Proposed Sale	250.51	3,500	876,785		Jul 24 04:24 PM
ANDERSON KERRII B	Director	Jul 01 '25	Sale	265.00	500	132,500	12,166	Jul 02 10:37 AM
ANDERSON KERRII B	Director	Jun 11 '25	Sale	260.00	500	130,000	12,666	Jun 12 10:07 AM
KERRII ANDERSON	Director	Jun 11 '25	Proposed Sale	259.37	1,000	259,370		Jun 11 04:29 PM
Caveney Brian J	EVP, Pres of ED, CMO & CSO	Jun 03 '25	Sale	247.00	2,000	494,000	30,067	Jun 05 08:19 AM
Caveney Brian J	Officer	Jun 03 '25	Proposed Sale	247.00	2,000	494,000		Jun 03 11:55 AM
EISENBERG GLENN A	Officer	May 13 '25	Proposed Sale	250.42	15,000	3,756,242		May 13 02:59 PM
Schechter Adam H	President & CEO	May 12 '25	Sale	248.73	6,105	1,518,497	98,962	May 13 10:01 AM
Schechter Adam H	Officer	May 12 '25	Proposed Sale	248.73	6,105	1,518,497		May 12 09:43 AM
van der Vaart Sandra D	EVP, Chief Legal Officer	May 01 '25	Sale	238.36	1,900	452,884	2,244	May 05 12:45 PM
Wilkinson Peter J	SVP, Chief Accounting Officer	May 01 '25	Sale	242.26	829	200,838	2,054	May 05 12:45 PM
van der Vaart Sandra D	Officer	May 01 '25	Proposed Sale	238.36	1,900	452,884		May 01 11:07 AM
Summy Amy B.	EVP, Chief Marketing Officer	Mar 28 '25	Sale	231.67	758	175,606	5,302	Mar 31 10:47 AM
Schroeder Mark S	EVP, Pres Diagnostics & COO	Mar 28 '25	Sale	231.67	2,635	610,450	4,960	Mar 31 10:39 AM
Schroeder Mark S	Officer	Mar 28 '25	Proposed Sale	231.67	2,635	610,450		Mar 28 11:27 AM
Summy Amy B.	Officer	Mar 28 '25	Proposed Sale	231.67	758	175,606		Mar 28 11:02 AM
ANDERSON KERRII B	Director	Mar 05 '25	Sale	255.63	500	127,817	13,166	Mar 07 08:16 AM
KERRII B ANDERSON	Director	Mar 05 '25	Proposed Sale	255.63	500	127,817		Mar 05 04:08 PM
Schroeder Mark S	EVP, Pres Diagnostics & COO	Feb 28 '25	Option Exercise	131.43	3,903	512,971	10,299	Mar 04 08:41 AM
Schroeder Mark S	EVP, Pres Diagnostics & COO	Feb 28 '25	Sale	249.23	5,339	1,330,639	4,960	Mar 04 08:41 AM
Schroeder Mark S	Officer	Feb 28 '25	Proposed Sale	249.23	5,339	1,330,639		Feb 28 10:15 AM
van der Vaart Sandra D	EVP, Chief Legal Officer	Feb 25 '25	Sale	251.30	1,314	330,208	2,171	Feb 27 10:07 AM
Summy Amy B.	EVP, Chief Marketing Officer	Feb 24 '25	Sale	250.40	226	56,590	4,544	Feb 26 09:03 AM
van der Vaart Sandra D	Officer	Feb 25 '25	Proposed Sale	251.30	1,314	330,208		Feb 25 10:15 AM
Summy Amy B.	Officer	Feb 24 '25	Proposed Sale	250.40	226	56,590		Feb 24 10:13 AM
Wilkinson Peter J	SVP, Chief Accounting Officer	Feb 18 '25	Option Exercise	163.63	1,413	231,209	3,406	Feb 20 03:24 PM
Wilkinson Peter J	SVP, Chief Accounting Officer	Feb 18 '25	Sale	246.10	1,413	347,739	1,993	Feb 20 03:24 PM

Open in Screener

VCYT

Veracyte Inc

Feb 17 • 01:45PM ET

36.40

+0.63 1.75 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: EXAS ILMN GH BIO NTRA MYGN CDNA QGEN FLGT CRL

| Held by: IJR VTI ARKK FBT IWM VB XBI ARKG VBK VXF

Index	RUT	P/E	95.86	EPS (ttm)	0.38	Insider Own	2.16%	Shs Outstand	79.03M	Perf Week	-0.91%
Market Cap	2.88B	Forward P/E	23.26	EPS next Y	1.56	Insider Trans	-10.01%	Shs Float	77.34M	Perf Month	-11.23%
Enterprise Value	2.55B	PEG	0.31	EPS next Q	0.41	Inst Own	111.00%	Short Float	7.28%	Perf Quarter	-8.71%
Income	30.32M	P/S	5.81	EPS this Y	436.38%	Inst Trans	6.13%	Short Ratio	6.60	Perf Half Y	20.44%
Sales	495.14M	P/B	2.29	EPS next Y	-5.90%	ROA	2.29%	Short Interest	5.63M	Perf YTD	-13.55%
Book/sh	15.91	P/C	7.85	EPS next 5Y	76.17%	ROE	2.49%	52W High	50.71 -28.23%	Perf Year	-11.47%
Cash/sh	4.64	P/FCF	29.30	EPS past 3/5Y	- -	ROIC	2.34%	52W Low	22.61 60.98%	Perf 3Y	42.96%
Dividend Est.	-	EV/EBITDA	35.53	Sales past 3/5Y	26.63% 29.93%	Gross Margin	66.85%	Volatility	4.65% 4.75%	Perf 5Y	-50.82%
Dividend TTM	-	EV/Sales	5.15	EPS Y/Y TTM	375.89%	Oper. Margin	9.98%	ATR (14)	1.72	Perf 10Y	475.90%
Dividend Ex-Date	-	Quick Ratio	5.94	Sales Y/Y TTM	16.41%	Profit Margin	6.12%	RSI (14)	39.62	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	6.23	EPS Q/Q	24.34%	SMA20	-5.07%	Beta	1.92	Target Price	49.18
Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	13.82%	SMA50	-11.74%	Rel Volume	0.41	Prev Close	35.77
Employees	824	LT Debt/Eq	0.03	Earnings	Feb 25 AMC	SMA200	6.98%	Avg Volume	853.78K	Price	36.40
IPO	Oct 30, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	59.13% 5.52%	Trades		Volume	232,905	Change	1.75%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Underweight	$48
Oct-20-25	Initiated	Canaccord Genuity	Hold	$40
Mar-20-25	Initiated	Craig Hallum	Buy	$45
Dec-05-24	Downgrade	Goldman	Buy → Neutral	$38 → $37
Nov-15-24	Initiated	Wolfe Research	Outperform	$50
Oct-16-24	Initiated	UBS	Buy	$43
Oct-10-24	Initiated	Guggenheim	Buy	$40
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral

Show Previous Ratings

Today 10:01AM	Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer (Zacks)
09:19AM	Henry Schein Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Feb-16-26 08:59AM	NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro (Zacks)
08:54AM	Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings (Zacks)
Feb-15-26 08:42AM	UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue (Insider Monkey)
09:39AM	Loading…
Feb-13-26 09:39AM	Here's How Charles River Stock Is Placed Ahead of Q4 Earnings (Zacks)
08:55AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Feb-11-26 01:34PM	BD Merges Biosciences & Diagnostics Business With Waters (Zacks)
Feb-10-26 12:20PM	GEHC Launches ReadyFix Fleet Management to Boost ECG Efficiency (Zacks)
11:22AM	Will DXCM Deliver Q4 Earnings Beat on G7 Stabilization, Volume Growth? (Zacks)
08:57AM	Labcorp's Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Feb-09-26 12:58PM	PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data (Zacks)
10:40AM	GEHC Strengthens AI Fetal Ultrasound via Diagnoly Collaboration (Zacks)
08:02AM	Strength in Cardiovascular Unit Likely to Lift MDT's Q3 Performance (Zacks)
Feb-06-26 09:45AM	Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings (Zacks)
05:40PM	Loading…
Feb-05-26 05:40PM	Mettler-Toledo (MTD) Q4 Earnings and Revenues Beat Estimates (Zacks)
12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
12:33PM	DXCM Upgrades Stelo With AI-Powered Smart Meal Logging Features (Zacks)
09:35AM	Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-04-26 05:15PM	Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 (Business Wire)
12:57PM	Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test (Zacks)
12:51PM	Here's Why You Should Add Masimo Stock to Your Portfolio Now (Zacks)
10:23AM	Edwards Lifesciences' Q4 Earnings on Deck: Here's What to Expect (Zacks)
09:45AM	Here's Why Veracyte (VCYT) is a Strong Growth Stock (Zacks)
08:47AM	Will Pharmacy and Consumer Wellness Segment Lead CVS' Q4 Earnings? (Zacks)
Feb-03-26 01:13PM	GEHC Wins FDA Clearance & CE Mark for Allia Moveo, Marks Global Debut (Zacks)
11:38AM	Zimmer Biomet to Report Q4 Earnings: Here's What to Expect (Zacks)
Feb-02-26 11:57AM	BD & Envetec Showcase Closed-Loop Recycling Solution for Lab Plastics (Zacks)
09:37AM	ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance (Zacks)
09:13AM	Can Cannabis Strength in Canada Drive Canopy's Q3 Earnings? (Zacks)
01:34PM	Loading…
Jan-30-26 01:34PM	GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test (Zacks)
09:55AM	Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now (Zacks)
08:28AM	HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash (Zacks)
Jan-29-26 01:32PM	Reasons to Retain Avanos Medical Stock in Your Portfolio Now (Zacks)
01:28PM	Organon Completes Divesture of JADA System to Laborie Medical (Zacks)
08:02AM	Here's How Align Technology Is Placed Ahead of Q4 Earnings (Zacks)
Jan-28-26 12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
11:26AM	QT Imaging & Olea Medical Partner to Enhance Cloud Imaging Platform (Zacks)
09:11AM	Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? (Zacks)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
07:46AM	PAHC Q2 Earnings Preview: Animal Health Momentum Likely to Aid Results (Zacks)
07:43AM	Here's How IDEXX Laboratories Is Placed Ahead of Q4 Earnings (Zacks)
07:27AM	Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings? (Zacks)
07:26AM	STERIS' Q3 Earnings on Deck: What's in Store for the Stock? (Zacks)
Jan-27-26 12:19PM	Here's Why You Should Add Merit Medical Stock to Your Portfolio Now (Zacks)
12:07PM	ISRG's da Vinci Gets FDA Nod for Advanced Cardiac Procedures (Zacks)
07:54AM	Resmed's Q2 Earnings on Deck: What's in Store for the Stock? (Zacks)
07:53AM	CLPT Gets EU MDR Certification for ClearPoint Navigation Software (Zacks)
Jan-26-26 12:10PM	Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-23-26 01:50PM	WST Launches Synchrony S1 Prefillable Syringe at Pharmapack (Zacks)
07:17AM	Can Specialty Diagnostics Strength Drive Thermo Fisher's Q4 Earnings? (Zacks)
Jan-22-26 11:08AM	Here's Why You Should Retain Integer Holdings Stock in Your Portfolio (Zacks)
09:50AM	Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term (Zacks)
03:25AM	Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating (Insider Monkey)
Jan-21-26 01:29PM	Centene Expands Palliative Care Access in Ohio Through Tuesday Health (Zacks)
11:43AM	BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System (Zacks)
Jan-19-26 12:40PM	Elekta Wins FDA Nod for Evo CT-Linac, Boosting U.S. Radiation Oncology (Zacks)
07:37AM	Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings? (Zacks)
Jan-14-26 01:11PM	Option Care Health Stock Earns Healthy RS Rating Upgrade (Investor's Business Daily)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
Jan-12-26 08:57AM	RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models (Zacks)
Jan-11-26 04:30PM	Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Business Wire)
Jan-08-26 09:00AM	The Zacks Rank Explained: How to Find Strong Buy Medical Stocks (Zacks)
Jan-07-26 12:24PM	BFLY to Extend 3D Imaging Capabilities to Butterfly Garden Developers (Zacks)
Jan-05-26 12:51PM	Here's Why You Should Retain Masimo Stock in Your Portfolio Now (Zacks)
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-30-25 11:48PM	Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT) (Insider Monkey)
10:42AM	RBOT Enters Strategic Software Partnership to Streamline Development (Zacks)
05:48AM	Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical (Zacks)
Dec-29-25 04:30PM	Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
07:23AM	3 Medical Instrument Stocks to Counter Industry Woes Using GenAI (Zacks)
Dec-26-25 12:20PM	EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy (Zacks)
Dec-23-25 02:08PM	Is This the Right Time to Add Veracyte Stock to Your Portfolio? (Zacks)
Dec-17-25 12:01PM	HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases (Zacks)
Dec-11-25 10:06AM	ISRG Gets FDA Clearance to Use da Vinci SP Robot for General Surgeries (Zacks)
Dec-10-25 12:40PM	PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor (Zacks)
08:59AM	Here's Why You Should Add Cencora Stock to Your Portfolio Now (Zacks)
Dec-08-25 08:23AM	Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus (Zacks)
Dec-03-25 11:59AM	EHC Opens New Lake Worth Rehab Hospital to Meet Rising Demand (Zacks)
Dec-02-25 09:45AM	Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term (Zacks)
Nov-19-25 12:24PM	TDOC Partners With TytoCare to Expand At-Home Exam Capabilities (Zacks)
Nov-13-25 11:07AM	Ensign Group Shares Decline 2.2% Despite Q3 Earnings Beat (Zacks) -5.74%
Nov-11-25 12:24PM	Encompass Health Shares Down 8% Despite Q3 Earnings & Revenue Beat (Zacks)
07:26AM	VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up (Zacks)
Nov-10-25 12:55PM	Tenet Healthcare Shares Down 5% Despite Q3 Earnings Beat (Zacks)
Nov-06-25 12:09PM	Pediatrix Medical Q3 Earnings Beat Estimates on Declining Expenses (Zacks) -9.45%
08:30AM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
Nov-05-25 12:03AM	Veracyte Inc (VCYT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +27.46%
Nov-04-25 06:25PM	Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates (Zacks)
05:31PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 04:15PM	Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing (Business Wire)
07:31AM	What To Expect From Veracyte Inc (VCYT) Q3 2025 Earnings (GuruFocus.com)
Oct-31-25 10:17AM	EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash (Zacks)
Oct-30-25 12:24PM	ALGN Stock Up on Q3 Earnings and Revenue Beat, Margins Crash (Zacks)
Oct-29-25 09:08AM	CHE Stock Falls on Q3 Earnings and Revenue Miss, Margins Crash (Zacks)
Oct-28-25 10:01AM	LH Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
Oct-24-25 01:53PM	ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates (Zacks)
Oct-22-25 10:56AM	ISRG Stock Gains on Q3 Earnings & Revenue Beat, Gross Margin Declines (Zacks)
09:23AM	Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up (Zacks)

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McGuire Annie	SVP, General Counsel	Dec 16 '25	Sale	43.13	10,739	463,204	67,760	Dec 17 04:35 PM
ANN MCGUIRE	Officer	Dec 16 '25	Proposed Sale	43.53	10,739	467,469		Dec 16 04:30 PM
EASTHAM KARIN	Director	Dec 05 '25	Option Exercise	7.77	20,000	155,400	33,554	Dec 08 04:34 PM
EASTHAM KARIN	Director	Dec 05 '25	Sale	45.45	20,000	908,923	13,554	Dec 08 04:34 PM
KARIN EASTHAM	Director	Dec 05 '25	Proposed Sale	47.41	20,000	948,200		Dec 05 04:26 PM
McGuire Annie	SVP, General Counsel	Dec 04 '25	Sale	47.30	1,422	67,261	78,499	Dec 04 07:44 PM
Chambers Rebecca	Chief Financial Officer	Dec 04 '25	Sale	46.84	13,278	621,955	109,496	Dec 04 07:44 PM
Stapley Marc	Chief Executive Officer	Dec 04 '25	Sale	47.09	7,668	361,076	318,603	Dec 04 07:44 PM
Leite John	Chief Commercial Officer-CLIA	Dec 04 '25	Sale	47.51	1,278	60,718	82,113	Dec 04 07:43 PM
ANN MCGUIRE	Officer	Dec 04 '25	Proposed Sale	47.75	1,422	67,900		Dec 04 04:39 PM
REBECCA CHAMBERS	Officer	Dec 04 '25	Proposed Sale	47.75	13,278	634,024		Dec 04 04:39 PM
MARC STAPLEY	Director	Dec 04 '25	Proposed Sale	47.75	7,668	366,147		Dec 04 04:38 PM
Leite John	Chief Commercial Officer-CLIA	Nov 25 '25	Sale	50.00	2,808	140,400	86,291	Nov 26 04:27 PM
JONES EVAN/ FA	Director	Nov 25 '25	Sale	50.25	1,106	55,576	29,362	Nov 26 04:27 PM
Evan Jones	Director	Nov 25 '25	Proposed Sale	49.38	5,000	246,900		Nov 25 07:25 PM
John Leite	Officer	Nov 25 '25	Proposed Sale	46.70	4,086	190,816		Nov 25 04:28 PM
Holstein Jens	Director	Nov 20 '25	Sale	42.36	10,000	423,563	27,199	Nov 21 04:19 PM
JENS HOLSTEIN	Director	Nov 20 '25	Proposed Sale	42.36	10,000	423,563		Nov 20 04:03 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 07 '25	Sale	40.21	5,818	233,929	43,847	Nov 12 04:25 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 10 '25	Sale	42.33	5,102	215,978	38,745	Nov 12 04:25 PM
McGuire Annie	SVP, General Counsel	Nov 05 '25	Sale	40.00	6,466	258,640	82,973	Nov 07 04:10 PM
JONES EVAN/ FA	Director	Nov 05 '25	Option Exercise	6.94	30,000	208,200	73,664	Nov 07 04:10 PM
JONES EVAN/ FA	Director	Nov 05 '25	Sale	45.06	43,196	1,946,288	30,468	Nov 07 04:10 PM
EASTHAM KARIN	Director	Nov 05 '25	Sale	40.02	9,674	387,191	13,554	Nov 07 04:10 PM
Chambers Rebecca	Chief Financial Officer	Nov 05 '25	Sale	41.00	7,000	287,000	126,158	Nov 07 04:10 PM
Evan Jones	Director	Nov 05 '25	Proposed Sale	46.04	43,196	1,988,744		Nov 05 09:47 PM
KARIN EASTHAM	Director	Nov 05 '25	Proposed Sale	36.12	9,674	349,425		Nov 05 04:18 PM
ANN MCGUIRE	Officer	Nov 05 '25	Proposed Sale	36.12	6,466	233,552		Nov 05 04:18 PM
REBECCA CHAMBERS	Officer	Nov 05 '25	Proposed Sale	36.12	7,000	252,840		Nov 05 04:17 PM
Febbo Phillip G.	Chief Scientific & Med Officer	Oct 06 '25	Sale	36.02	8,349	300,709	92,441	Oct 07 04:27 PM
PHILLIP FEBBO	Officer	Oct 06 '25	Proposed Sale	36.00	8,349	300,564		Oct 06 04:19 PM
Leite John	Chief Commercial Officer-CLIA	Oct 01 '25	Sale	35.00	2,539	88,865	89,099	Oct 03 04:16 PM
EPSTEIN ROBERT S	Director	Oct 01 '25	Option Exercise	7.94	10,000	79,400	83,919	Oct 03 04:16 PM
EPSTEIN ROBERT S	Director	Oct 01 '25	Sale	35.08	21,473	753,204	62,446	Oct 03 04:16 PM
McGuire Annie	SVP, General Counsel	Oct 01 '25	Sale	35.00	2,160	75,608	89,439	Oct 03 04:16 PM
ROBERT S EPSTEIN	Director	Oct 01 '25	Proposed Sale	34.33	21,473	737,168		Oct 01 04:27 PM
John Leite	Officer	Oct 01 '25	Proposed Sale	34.33	2,539	87,164		Oct 01 04:27 PM
ANN MCGUIRE	Officer	Oct 01 '25	Proposed Sale	34.33	2,160	74,153		Oct 01 04:26 PM
McGuire Annie	SVP, General Counsel	Sep 19 '25	Sale	33.69	2,283	76,920	91,599	Sep 23 04:18 PM
ANN MCGUIRE	Officer	Sep 19 '25	Proposed Sale	33.23	2,283	75,864		Sep 19 04:25 PM
Stapley Marc	Chief Executive Officer	Sep 04 '25	Sale	30.41	7,667	233,133	334,185	Sep 08 04:33 PM
MARC STAPLEY	Director	Sep 04 '25	Proposed Sale	30.62	7,667	234,764		Sep 04 04:26 PM
EASTHAM KARIN	Director	Jun 13 '25	Sale	26.66	4,590	122,388	13,907	Jun 17 04:21 PM
Bhanji Muna	Director	Jun 13 '25	Sale	26.67	4,589	122,367	29,989	Jun 17 04:21 PM
KARIN EASTHAM	Director	Jun 13 '25	Proposed Sale	26.69	4,590	122,507		Jun 13 04:46 PM
MUNA BHANJI	Director	Jun 13 '25	Proposed Sale	26.69	4,589	122,480		Jun 13 04:45 PM
Leite John	Chief Commercial Officer-CLIA	Jun 04 '25	Sale	27.20	2,809	76,410	94,540	Jun 06 04:19 PM
JOHN LEITE	Officer	Jun 04 '25	Proposed Sale	26.50	2,809	74,438		Jun 04 04:21 PM
Leite John	Chief Commercial Officer-CLIA	Mar 07 '25	Sale	31.66	7,411	234,630	100,249	Mar 10 04:43 PM
JOHN LEITE	Officer	Mar 07 '25	Proposed Sale	32.51	7,411	240,932		Mar 07 04:17 PM
ANN MCGUIRE	Officer	Mar 04 '25	Proposed Sale	33.56	1,142	38,326		Mar 04 05:12 PM
MARC STAPLEY	Director	Mar 04 '25	Proposed Sale	33.56	52,697	1,768,511		Mar 04 05:07 PM
PHILLIP FEBBO	Officer	Mar 04 '25	Proposed Sale	33.56	8,037	269,722		Mar 04 05:07 PM
Leite John	Chief Commercial Officer-CLIA	Feb 27 '25	Sale	33.84	5,746	194,445	79,070	Mar 03 04:30 PM

Open in Screener

SERA

Sera Prognostics Inc

Feb 17 • 01:44PM ET

2.71

+0.06 2.26 %

Healthcare • Medical Devices • USA • NASD

SERA Sera Prognostics Inc daily Stock Chart

Peers: ILMN NTRA GH BIO EXAS ONC CDNA QDEL RCKT VERU

| Held by: VTI VXF IWC AVSC

Index	-	P/E	-	EPS (ttm)	-0.77	Insider Own	30.81%	Shs Outstand	37.60M	Perf Week	1.12%
Market Cap	104.60M	Forward P/E	-	EPS next Y	-0.70	Insider Trans	-1.61%	Shs Float	26.70M	Perf Month	-23.01%
Enterprise Value	63.75M	PEG	-	EPS next Q	-0.19	Inst Own	41.31%	Short Float	1.18%	Perf Quarter	-8.14%
Income	-32.63M	P/S	1045.96	EPS this Y	29.14%	Inst Trans	-2.46%	Short Ratio	6.41	Perf Half Y	20.44%
Sales	0.10M	P/B	1.27	EPS next Y	0.43%	ROA	-34.87%	Short Interest	0.32M	Perf YTD	-8.14%
Book/sh	2.13	P/C	2.42	EPS next 5Y	16.59%	ROE	-47.69%	52W High	4.46 -39.24%	Perf Year	-32.75%
Cash/sh	1.12	P/FCF	-	EPS past 3/5Y	4.46% -13.01%	ROIC	-38.55%	52W Low	1.37 97.81%	Perf 3Y	-24.72%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-2.08% 16.42%	Gross Margin	-905.26%	Volatility	7.36% 7.40%	Perf 5Y	-
Dividend TTM	-	EV/Sales	637.46	EPS Y/Y TTM	22.41%	Oper. Margin	-38918.95%	ATR (14)	0.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.89	Sales Y/Y TTM	1.06%	Profit Margin	-34343.16%	RSI (14)	42.85	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.89	EPS Q/Q	33.19%	SMA20	-5.23%	Beta	1.00	Target Price	5.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-44.83%	SMA50	-14.36%	Rel Volume	0.18	Prev Close	2.65
Employees	64	LT Debt/Eq	0.03	Earnings	Nov 13 AMC	SMA200	-4.56%	Avg Volume	49.22K	Price	2.71
IPO	Jul 15, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	19.03% -68.25%	Trades		Volume	5,975	Change	2.26%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-15-25	Initiated	Jefferies	Buy	$5
Mar-30-22	Downgrade	Citigroup	Buy → Neutral	$18 → $4
Nov-19-21	Initiated	Oppenheimer	Outperform	$19
Oct-15-21	Resumed	Cowen	Outperform

Today 08:05AM	SERA PROGNOSTICS TO PRESENT AT TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE (PR Newswire)
Jan-07-26 08:30AM	Landmark Study Finds PreTRM Blood Test Reduces Earliest Preterm Births and Newborn Complications (PR Newswire) +11.49%
Nov-26-25 12:00PM	Sera Prognostics (SERA) Upgraded to Buy: Here's Why (Zacks)
Nov-24-25 08:00AM	Sera Announces Publication Acceptance for PRIME Study (PR Newswire)
Nov-20-25 04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire)
12:05AM	Loading…
Nov-14-25 12:05AM	Sera Prognostics Inc (SERA) Q3 2025 Earnings Call Highlights: Strategic Medicaid Pilots and ... (GuruFocus.com)
Nov-13-25 05:55PM	Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -5.45%
04:05PM	SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS (PR Newswire)
Nov-04-25 10:05AM	Premier, Inc. (PINC) Tops Q1 Earnings and Revenue Estimates (Zacks) -5.63%
Oct-30-25 04:05PM	SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025 (PR Newswire)
Oct-29-25 07:40AM	CVS Health (CVS) Surpasses Q3 Earnings and Revenue Estimates (Zacks) -6.93%
Oct-01-25 08:05AM	Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer (PR Newswire)
Aug-28-25 08:05AM	SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE (PR Newswire) +8.45%
Aug-06-25 05:50PM	Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +12.24% -5.45%
04:05PM	SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS (PR Newswire)
04:05PM	Loading…
Jul-29-25 04:05PM	Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2025 Financial Results on August 6, 2025 (PR Newswire) -7.64%
May-29-25 09:35AM	After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA) (Zacks)
08:30AM	SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES (PR Newswire)
May-14-25 04:05PM	SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE (PR Newswire) +6.00%
May-13-25 09:35AM	Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround (Zacks)
May-08-25 04:40PM	SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER (PR Newswire) -11.67%
03:36AM	Sera Prognostics Inc (SERA) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
May-07-25 05:55PM	Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS (PR Newswire)
Apr-24-25 08:30AM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025 (PR Newswire)
Apr-15-25 01:54AM	Sera Prognostics: Initiating With Hold, Potential Of PreTRM Test, But Uncertain Commercial Timeline (Seeking Alpha)
Mar-19-25 07:13PM	Sera Prognostics Inc (SERA) Q4 2024 Earnings Call Transcript (SeekingAlpha) -5.07%
05:20PM	Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:10PM	SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN (PR Newswire)
04:05PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
08:30AM	Loading…
Mar-11-25 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025 (PR Newswire)
Feb-21-25 08:30AM	Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference (PR Newswire)
Feb-10-25 10:41PM	Sera Prognostics Announces Pricing of $50 Million Public Offering (PR Newswire) -9.44%
04:01PM	Sera Prognostics Announces Proposed Public Offering (PR Newswire)
Jan-27-25 05:02PM	Sera Prognostics to Host Virtual R&D Day on January 31 (PR Newswire) -5.19%
Jan-06-25 08:30AM	Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-04-24 04:01PM	Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting (PR Newswire) +14.78%
Dec-02-24 08:30AM	Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-26-24 05:00AM	5 investing trends for 2025and 15 stocks to help you bet on them (Fortune)
Nov-15-24 08:30AM	Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (PR Newswire)
Nov-06-24 06:00PM	Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +14.25% -12.70%
04:05PM	SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
Oct-28-24 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024 (PR Newswire)
Sep-04-24 04:53PM	Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-08-24 08:30AM	Sera Prognostics to Participate in Panel Discussion at UBS Genomic Medicine Summit on August 14, 2024 (PR Newswire)
Aug-07-24 05:50PM	Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
Jul-25-24 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024 (PR Newswire)
Jul-09-24 08:30AM	Sera Prognostics PreTRM Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial (PR Newswire)
Jul-01-24 08:30AM	SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION (PR Newswire)
Jun-16-24 06:17AM	3 Stocks Under $10 With the Potential to Make You a Millionaire (InvestorPlace)
May-28-24 08:30AM	SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES (PR Newswire)
May-10-24 03:10PM	Sera Prognostics Inc Reports Q1 2024 Results: A Closer Look at Financials and Strategic Moves (GuruFocus.com) -5.41%
May-09-24 10:44AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.27%
May-08-24 08:57PM	SERA Stock Earnings: Sera Prognostics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
Apr-29-24 02:15PM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024 (PR Newswire)
Mar-29-24 01:32AM	Chief Scientific Officer John Boniface Sells 77,136 Shares of Sera Prognostics Inc (SERA) (GuruFocus.com)
Mar-27-24 01:27AM	Chief Scientific Officer John Boniface Sells 22,163 Shares of Sera Prognostics Inc (SERA) (GuruFocus.com)
Mar-25-24 12:00PM	Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know (Zacks) -8.50%
Mar-21-24 09:57AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-20-24 08:54PM	SERA Stock Earnings: Sera Prognostics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:33PM	Sera Prognostics Inc Reports Modest Revenue Growth Amid Operational Streamlining (GuruFocus.com)
05:20PM	Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Mar-12-24 11:40AM	25 Countries With Highest Abortion Rates (Insider Monkey)
Mar-04-24 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024 (PR Newswire)
Feb-29-24 11:14AM	Sera Prognostics To Present at TD Cowen 44th Annual Healthcare Conference (PR Newswire)
Dec-11-23 12:00PM	Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy (Zacks)
Dec-06-23 01:19PM	Why Is Sera Prognostics (SERA) Stock Up 260% Today? (InvestorPlace) +161.43%
08:30AM	SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS (PR Newswire)
Nov-22-23 01:00PM	SERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE (PR Newswire)
Nov-12-23 10:59AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 06:29PM	Sera Prognostics Inc (SERA) Reports Q3 2023 Financial Results: Revenue Declines as Cost ... (GuruFocus.com) -7.61%
04:05PM	SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Oct-25-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023 (PR Newswire) +6.06%
Sep-21-23 08:30AM	SERA PROGNOSTICS TO PRESENT AT CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE 2023 (PR Newswire)
Aug-31-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -32.38% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -6.32%
Aug-30-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -38.49% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-09-23 05:50PM	Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Jul-31-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2023 Financial Results on August 9, 2023 (PR Newswire)
May-25-23 04:15PM	Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue (PR Newswire) -5.08%
May-15-23 05:15PM	Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO (PR Newswire)
May-10-23 06:05PM	Sera Prognostics, Inc. (SERA) Reports Q1 Loss (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
May-04-23 07:31AM	We're Not Very Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate (Simply Wall St.)
Apr-27-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023 (PR Newswire)
Apr-24-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -13.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-27-23 12:00PM	All You Need to Know About Sera Prognostics, Inc. (SERA) Rating Upgrade to Buy (Zacks)
02:27AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 06:29AM	Sera Prognostics Full Year 2022 Earnings: Revenues Miss Expectations (Simply Wall St.)
Mar-22-23 05:35PM	Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.77%
04:05PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
Mar-09-23 04:05PM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023 (PR Newswire)
Feb-23-23 04:20PM	SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES (PR Newswire) -7.22%
Feb-18-23 07:43AM	Individual investors in Sera Prognostics, Inc. (NASDAQ:SERA) are its biggest bettors, and their bets paid off as stock gained 179% last week (Simply Wall St.)
Feb-15-23 08:30AM	Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL (PR Newswire) +73.28%
Nov-29-22 08:30AM	FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS (PR Newswire) -7.63%
Nov-15-22 08:30AM	SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS (PR Newswire)

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harrison Robert Gardner	Chief Information Officer	Jan 27 '26	Sale	2.97	2,000	5,940	82,788	Jan 27 05:12 PM
ROBERT HARRISON	Officer	Jan 27 '26	Proposed Sale	3.09	2,000	6,180		Jan 27 04:18 PM
Harrison Robert Gardner	Chief Information Officer	Dec 30 '25	Sale	3.00	2,000	6,000	84,788	Dec 30 06:41 PM
ROBERT GARDNER HARRISON	Officer	Dec 30 '25	Proposed Sale	3.27	2,000	6,540		Dec 30 04:24 PM
Lindgardt Zhenya	Chief Executive Officer	Dec 10 '25	Sale	3.31	4,155	13,753	763,926	Dec 11 07:58 PM
Kearney Paul	Chief Data Officer	Dec 10 '25	Sale	3.31	1,213	4,015	167,383	Dec 11 07:57 PM
Jackson Benjamin	General Counsel	Dec 10 '25	Sale	3.31	892	2,953	118,866	Dec 11 07:57 PM
Harrison Robert Gardner	Chief Information Officer	Dec 10 '25	Sale	3.31	616	2,039	86,788	Dec 11 07:56 PM
Boniface John J.	Chief Scientific Officer	Dec 10 '25	Sale	3.31	1,332	4,409	150,397	Dec 11 07:56 PM
Aerts Austin	Chief Financial Officer	Dec 10 '25	Sale	3.31	873	2,890	272,214	Dec 11 07:56 PM
Lindgardt Zhenya	Officer	Dec 10 '25	Proposed Sale	3.31	4,155	13,741		Dec 11 07:54 PM
Kearney Paul	Officer	Dec 10 '25	Proposed Sale	3.31	1,213	4,012		Dec 11 07:54 PM
Jackson Benjamin	Officer	Dec 10 '25	Proposed Sale	3.31	892	2,950		Dec 11 07:54 PM
Harrison Robert Gardner	Officer	Dec 10 '25	Proposed Sale	3.31	616	2,037		Dec 11 07:53 PM
Boniface John J.	Officer	Dec 10 '25	Proposed Sale	3.31	1,332	4,405		Dec 11 07:53 PM
Aerts Austin	Officer	Dec 10 '25	Proposed Sale	3.31	873	2,887		Dec 11 07:53 PM
Lindgardt Zhenya	Chief Executive Officer	Dec 09 '25	Sale	3.04	28,215	85,774	768,081	Dec 10 07:24 PM
Aerts Austin	Chief Financial Officer	Dec 09 '25	Sale	3.04	5,232	15,905	273,087	Dec 10 07:24 PM
Lindgardt Zhenya	Officer	Dec 09 '25	Proposed Sale	3.04	28,215	85,838		Dec 10 07:23 PM
Aerts Austin	Officer	Dec 09 '25	Proposed Sale	3.04	5,232	15,917		Dec 10 07:23 PM
Lawrence Sandra AJ	Director	Dec 08 '25	Sale	3.05	1,560	4,758	19,593	Dec 08 07:06 PM
SANDRA AJ LAWRENCE	Director	Dec 08 '25	Proposed Sale	3.08	1,560	4,805		Dec 08 04:38 PM
Mirza Mansoor Raza	Director	Dec 05 '25	Sale	3.05	292	891	57,740	Dec 05 05:25 PM
Mirza Mansoor Raza	Director	Dec 05 '25	Proposed Sale	3.05	292	892		Dec 05 05:24 PM
Harrison Robert Gardner	Chief Information Officer	Dec 02 '25	Sale	2.93	2,000	5,860	87,404	Dec 03 04:14 PM
Kearney Paul	Chief Data Officer	Dec 02 '25	Option Exercise	1.62	32,203	52,169	200,799	Dec 03 04:14 PM
Kearney Paul	Chief Data Officer	Dec 02 '25	Sale	2.94	32,203	94,677	168,596	Dec 03 04:14 PM
PAUL KEARNEY	Officer	Dec 02 '25	Proposed Sale	2.94	32,203	94,609		Dec 02 05:40 PM
ROBERT GARDNER HARRISON	Officer	Dec 02 '25	Proposed Sale	3.21	2,000	6,420		Dec 02 04:22 PM
Kearney Paul	Chief Data Officer	Nov 26 '25	Option Exercise	1.62	1,986	3,217	170,582	Nov 26 06:53 PM
Kearney Paul	Chief Data Officer	Nov 26 '25	Sale	3.51	1,986	6,971	168,596	Nov 26 06:53 PM
PAUL KEARNEY	Officer	Nov 26 '25	Proposed Sale	3.40	34,189	116,243		Nov 26 04:18 PM
Lindgardt Zhenya	Chief Executive Officer	Nov 10 '25	Sale	2.62	11,594	30,376	796,296	Nov 12 04:25 PM
Kearney Paul	Chief Data Officer	Nov 10 '25	Sale	2.62	7,073	18,531	168,596	Nov 12 04:24 PM
Jackson Benjamin	General Counsel	Nov 10 '25	Sale	2.62	7,059	18,495	119,758	Nov 12 04:24 PM
Harrison Robert Gardner	Chief Information Officer	Nov 10 '25	Sale	2.62	6,528	17,103	89,404	Nov 12 04:24 PM
Boniface John J.	Chief Scientific Officer	Nov 10 '25	Sale	2.62	7,767	20,350	151,726	Nov 12 04:23 PM
Aerts Austin	Chief Financial Officer	Nov 10 '25	Sale	2.62	6,351	16,640	278,319	Nov 12 04:23 PM
Lindgardt Zhenya	Officer	Nov 10 '25	Proposed Sale	2.62	11,594	30,408		Nov 12 04:22 PM
Kearney Paul	Officer	Nov 10 '25	Proposed Sale	2.62	7,073	18,550		Nov 12 04:21 PM
Jackson Benjamin	Officer	Nov 10 '25	Proposed Sale	2.62	7,059	18,514		Nov 12 04:21 PM
Harrison Robert Gardner	Officer	Nov 10 '25	Proposed Sale	2.62	6,528	17,121		Nov 12 04:21 PM
Boniface John J.	Officer	Nov 10 '25	Proposed Sale	2.62	7,767	20,371		Nov 12 04:21 PM
Aerts Austin	Officer	Nov 10 '25	Proposed Sale	2.62	6,351	16,657		Nov 12 04:20 PM
Mirza Mansoor Raza	Director	Nov 05 '25	Sale	3.04	221	672	58,032	Nov 06 05:05 PM
Mirza Mansoor Raza	Director	Nov 05 '25	Proposed Sale	3.04	221	672		Nov 06 05:04 PM
Harrison Robert Gardner	Chief Information Officer	Nov 04 '25	Sale	3.07	2,000	6,140	95,932	Nov 04 06:35 PM
ROBERT GARDNER HARRISON	Officer	Nov 04 '25	Proposed Sale	3.20	2,000	6,400		Nov 04 04:32 PM
Harrison Robert Gardner	Chief Information Officer	Oct 07 '25	Sale	3.18	2,000	6,360	97,932	Oct 08 04:35 PM
ROBERT GARDNER HARRISON	Officer	Oct 07 '25	Proposed Sale	3.26	2,000	6,520		Oct 07 04:18 PM
Mirza Mansoor Raza	Director	Oct 06 '25	Sale	3.16	227	717	58,253	Oct 06 04:15 PM
Mirza Mansoor Raza	Director	Oct 06 '25	Proposed Sale	3.16	227	718		Oct 06 04:13 PM
Lindgardt Zhenya	Chief Executive Officer	Sep 11 '25	Sale	3.13	3,246	10,160	807,890	Sep 12 04:36 PM
Kearney Paul	Chief Data Officer	Sep 11 '25	Sale	3.13	1,271	3,978	175,669	Sep 12 04:36 PM
Jackson Benjamin	General Counsel	Sep 11 '25	Sale	3.13	934	2,923	126,817	Sep 12 04:35 PM
Harrison Robert Gardner	Chief Information Officer	Sep 11 '25	Sale	3.13	645	2,019	99,932	Sep 12 04:35 PM
Boniface John J.	Chief Scientific Officer	Sep 11 '25	Sale	3.13	1,395	4,366	159,493	Sep 12 04:35 PM
Aerts Austin	Chief Financial Officer	Sep 11 '25	Sale	3.13	915	2,864	284,670	Sep 12 04:34 PM
Lindgardt Zhenya	Officer	Sep 11 '25	Proposed Sale	3.13	3,246	10,156		Sep 12 04:33 PM
Kearney Paul	Officer	Sep 11 '25	Proposed Sale	3.13	1,271	3,977		Sep 12 04:33 PM
Jackson Benjamin	Officer	Sep 11 '25	Proposed Sale	3.13	934	2,922		Sep 12 04:32 PM
Harrison Robert Gardner	Officer	Sep 11 '25	Proposed Sale	3.13	645	2,018		Sep 12 04:32 PM
Boniface John J.	Officer	Sep 11 '25	Proposed Sale	3.13	1,395	4,365		Sep 12 04:32 PM
Aerts Austin	Officer	Sep 11 '25	Proposed Sale	3.13	915	2,863		Sep 12 04:31 PM
Lindgardt Zhenya	Chief Executive Officer	Sep 09 '25	Sale	3.15	21,158	66,648	811,136	Sep 09 07:31 PM
Aerts Austin	Chief Financial Officer	Sep 09 '25	Sale	3.15	5,263	16,578	285,585	Sep 09 07:30 PM
Lindgardt Zhenya	Officer	Sep 09 '25	Proposed Sale	3.15	21,158	66,572		Sep 09 07:30 PM
Aerts Austin	Officer	Sep 09 '25	Proposed Sale	3.15	5,263	16,560		Sep 09 07:30 PM
Lawrence Sandra AJ	Director	Sep 09 '25	Sale	3.05	3,899	11,892	18,814	Sep 09 06:51 PM
Harrison Robert Gardner	Chief Information Officer	Sep 09 '25	Sale	3.05	2,000	6,100	100,577	Sep 09 06:51 PM
ROBERT GARDNER HARRISON	Officer	Sep 09 '25	Proposed Sale	3.17	2,000	6,340		Sep 09 04:26 PM
SANDRA AJ LAWRENCE	Director	Sep 09 '25	Proposed Sale	3.17	3,899	12,360		Sep 09 04:25 PM
Mirza Mansoor Raza	Director	Sep 05 '25	Sale	3.35	222	744	58,480	Sep 05 06:37 PM
Mirza Mansoor Raza	Director	Sep 05 '25	Proposed Sale	3.35	222	744		Sep 05 06:37 PM
Kearney Paul	Chief Data Officer	Sep 02 '25	Sale	3.49	1,458	5,088	176,940	Sep 03 04:41 PM
PAUL KEARNEY	Officer	Sep 02 '25	Proposed Sale	3.23	1,458	4,709		Sep 02 04:42 PM
Kearney Paul	Chief Data Officer	Aug 29 '25	Sale	3.49	10,542	36,792	178,398	Sep 02 04:24 PM
PAUL KEARNEY	Officer	Aug 29 '25	Proposed Sale	3.08	10,542	32,469		Aug 29 04:16 PM
Harrison Robert Gardner	Chief Information Officer	Aug 20 '25	Sale	2.22	6,000	13,320	102,577	Aug 20 06:55 PM
ROBERT GARDNER HARRISON	Officer	Aug 20 '25	Proposed Sale	2.25	6,000	13,500		Aug 20 04:20 PM
Lindgardt Zhenya	Chief Executive Officer	Aug 08 '25	Sale	2.54	8,571	21,770	832,294	Aug 11 04:37 PM
Kearney Paul	Chief Data Officer	Aug 08 '25	Sale	2.54	6,460	16,408	188,940	Aug 11 04:37 PM
Jackson Benjamin	General Counsel	Aug 08 '25	Sale	2.54	6,447	16,375	127,751	Aug 11 04:37 PM
Harrison Robert Gardner	Chief Information Officer	Aug 08 '25	Sale	2.54	5,962	15,143	108,577	Aug 11 04:36 PM
Boniface John J.	Chief Scientific Officer	Aug 08 '25	Sale	2.54	7,094	18,019	160,888	Aug 11 04:36 PM
Aerts Austin	Chief Financial Officer	Aug 08 '25	Sale	2.54	5,800	14,732	290,848	Aug 11 04:35 PM
Lindgardt Zhenya	Officer	Aug 08 '25	Proposed Sale	2.54	8,571	21,773		Aug 11 04:35 PM
Kearney Paul	Officer	Aug 08 '25	Proposed Sale	2.54	6,460	16,410		Aug 11 04:35 PM
Jackson Benjamin	Officer	Aug 08 '25	Proposed Sale	2.54	6,447	16,377		Aug 11 04:35 PM
Harrison Robert Gardner	Officer	Aug 08 '25	Proposed Sale	2.54	5,962	15,145		Aug 11 04:34 PM
Boniface John J.	Officer	Aug 08 '25	Proposed Sale	2.54	7,094	18,021		Aug 11 04:34 PM
Aerts Austin	Officer	Aug 08 '25	Proposed Sale	2.54	5,800	14,734		Aug 11 04:34 PM
Mirza Mansoor Raza	Director	Aug 05 '25	Sale	2.50	225	562	58,702	Aug 05 06:07 PM
Mirza Mansoor Raza	Director	Aug 05 '25	Proposed Sale	2.50	225	563		Aug 05 06:06 PM
Mirza Mansoor Raza	Director	Jul 07 '25	Sale	2.36	234	552	58,927	Jul 08 05:08 PM
Mirza Mansoor Raza	Director	Jul 07 '25	Proposed Sale	2.36	234	552		Jul 08 05:07 PM
Jackson Benjamin	General Counsel	Jun 10 '25	Sale	1.48	965	1,428	134,198	Jun 12 06:54 PM
Boniface John J.	Chief Scientific Officer	Jun 10 '25	Sale	1.48	1,439	2,130	167,982	Jun 12 06:54 PM
Lindgardt Zhenya	Officer	Jun 10 '25	Proposed Sale	1.48	3,344	4,964		Jun 11 08:17 PM
Aerts Austin	Officer	Jun 10 '25	Proposed Sale	1.48	945	1,403		Jun 11 08:17 PM

Open in Screener

GH

Guardant Health Inc

Feb 17 • 01:45PM ET

108.46

+3.61 3.45 %

Healthcare • Diagnostics & Research • USA • NASD

GH Guardant Health Inc daily Stock Chart

Peers: ILMN QGEN EXAS FLGT BIO SRPT MYGN NTRA CDNA TXG

| Held by: VTI VB IWM VBK VXF IWO VTWO SCHA ARKG CGGR

Index	RUT	P/E	-	EPS (ttm)	-3.21	Insider Own	3.80%	Shs Outstand	125.01M	Perf Week	2.96%
Market Cap	14.03B	Forward P/E	-	EPS next Y	-2.71	Insider Trans	-13.26%	Shs Float	124.46M	Perf Month	-3.14%
Enterprise Value	14.78B	PEG	-	EPS next Q	-0.77	Inst Own	98.57%	Short Float	7.62%	Perf Quarter	15.23%
Income	-398.79M	P/S	15.55	EPS this Y	13.38%	Inst Trans	5.91%	Short Ratio	4.57	Perf Half Y	84.21%
Sales	902.57M	P/B	-	EPS next Y	12.20%	ROA	-28.33%	Short Interest	9.48M	Perf YTD	6.19%
Book/sh	-2.84	P/C	24.19	EPS next 5Y	23.02%	ROE	-4584.47%	52W High	120.74 -10.17%	Perf Year	125.40%
Cash/sh	4.48	P/FCF	-	EPS past 3/5Y	3.89% -33.61%	ROIC	-42.18%	52W Low	34.88 210.96%	Perf 3Y	281.24%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	25.52% 28.08%	Gross Margin	63.76%	Volatility	5.89% 5.55%	Perf 5Y	-35.67%
Dividend TTM	-	EV/Sales	16.37	EPS Y/Y TTM	24.17%	Oper. Margin	-49.02%	ATR (14)	5.87	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.12	Sales Y/Y TTM	30.38%	Profit Margin	-44.18%	RSI (14)	51.49	Recom	1.48
Dividend Gr. 3/5Y	- -	Current Ratio	3.50	EPS Q/Q	15.15%	SMA20	-1.15%	Beta	1.66	Target Price	126.30
Payout	-	Debt/Eq	-	Sales Q/Q	38.50%	SMA50	1.92%	Rel Volume	0.69	Prev Close	104.85
Employees	2021	LT Debt/Eq	-	Earnings	Feb 19 AMC	SMA200	50.32%	Avg Volume	2.07M	Price	108.46
IPO	Oct 04, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.28% 12.56%	Trades		Volume	961,243	Change	3.45%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Initiated	Robert W. Baird	Outperform	$120
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line	$105
Dec-02-25	Resumed	Morgan Stanley	Overweight	$130
Sep-25-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$75
Sep-22-25	Resumed	Wells Fargo	Overweight	$72
Apr-10-25	Initiated	Mizuho	Outperform	$55
Jan-23-25	Initiated	Barclays	Overweight	$60
Jun-28-24	Upgrade	Guggenheim	Neutral → Buy	$36
Jun-03-24	Resumed	Jefferies	Buy	$32
Apr-24-24	Resumed	Craig Hallum	Buy	$28
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform	$27
Sep-28-23	Initiated	Bernstein	Outperform	$34
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$40
Jul-05-23	Resumed	JP Morgan	Overweight	$65
May-26-23	Upgrade	Citigroup	Neutral → Buy	$28 → $40
May-05-23	Initiated	UBS	Buy	$40
Mar-09-23	Downgrade	Citigroup	Buy → Neutral	$60 → $33
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$36

Show Previous Ratings

Today 10:09AM	What Makes Guardant Health (GH) a Good Healthcare Holding (Insider Monkey)
08:04AM	Palo Alto Earnings Due. How Will Deal Blitz Impact Guidance? (Investor's Business Daily)
Feb-14-26 09:37AM	Boeing Holds In Buy Zone, Leads 5 Stocks To Watch In Short Trading Week (Investor's Business Daily)
Feb-13-26 08:22PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
03:38PM	IPO Stock Of The Week: Health Care Leader BrightSpring Eyes New Buy Point (Investor's Business Daily)
10:20AM	Loading…
10:20AM	Walmart Stock, Parade Of Gold Leaders Headline Another Busy Earnings Calendar (Investor's Business Daily)
Feb-12-26 02:35PM	Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open (PR Newswire)
10:00AM	Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know (Zacks)
09:10AM	Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates (Zacks)
Feb-11-26 07:28PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Feb-06-26 07:15AM	Long-Time Bear On Palantir Stock Says More Selling Still To Come (Investor's Business Daily)
Feb-05-26 07:32PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) -7.34%
05:35PM	Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-04-26 05:45PM	Palantir Retreats After Q4 Earnings Pop. Will 'N of 1' Story Work? (Investor's Business Daily) -6.10%
Feb-03-26 04:05PM	Guardant Health to Participate in Upcoming Investor Conferences (Business Wire)
08:03AM	Loading…
08:03AM	Stock Market Week: Dow Rally Aces Ninth Month (Investor's Business Daily)
Feb-02-26 04:27PM	Palantir Rebuts Bears With Earnings Beat, Guidance Above Views (Investor's Business Daily)
08:05AM	Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions (Business Wire)
Jan-30-26 05:04AM	Should You Buy Guardant Health Before Feb. 19? (Motley Fool)
Jan-29-26 04:05PM	Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 (Business Wire)
Jan-23-26 07:40AM	Wall Street Has a Positive Opinion on Guardant Health (GH) (Insider Monkey)
Jan-22-26 12:51PM	FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer (Benzinga)
08:05AM	Guardant Health Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for BRAFTOVI (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer (Business Wire)
Jan-20-26 08:54AM	Strong Results and Improved Guidance Lifted Guardant Health (GH) in Q4 (Insider Monkey)
04:58AM	Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build (Insider Monkey)
Jan-19-26 08:05AM	Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform (Business Wire)
Jan-17-26 05:30AM	Supersize CEO Pay Packages Aren't Paying Off for Shareholders (The Wall Street Journal)
Jan-14-26 10:35PM	Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group (StockStory)
Jan-11-26 05:00PM	Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results (Business Wire)
01:10AM	Guggenheim Analyst is Bullish on Guardant Health, Inc. (GH) (Insider Monkey)
08:00AM	Loading…
Jan-10-26 08:00AM	Google, Shopify Lead Big 2025 Winners Near New Buy Points (Investor's Business Daily)
Jan-09-26 02:24PM	Clinical Labs Hope to Head Off Looming Medicare Cuts (Barrons.com)
Jan-08-26 01:30PM	Guardant Health Catapults 234%; Sets Up With Strong Sales Outlook (Investor's Business Daily)
10:31AM	Cathie Wood Dumps $12.7 Million Worth of Meta Stock Amid Ray-Ban Smart Glasses Delay, Ark Loads Up On This Gaming Platform (Benzinga)
08:05AM	Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families (Business Wire)
Jan-06-26 06:54PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) +10.27%
Dec-31-25 11:33AM	Canaccord Names Guardant Health (GH) Top Life Science Pick, Cites Strong Growth and Low Downside (Insider Monkey)
Dec-29-25 04:05PM	Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
07:59AM	Stock Market Today: Dow Down From Record Highs; Nvidia, Tesla Slide (Live Coverage) (Investor's Business Daily)
Dec-27-25 08:05AM	Palantir, Nvidia Lead 5 Stocks Near Buy Points Heading Into Final Days Of 2025 (Investor's Business Daily)
Dec-26-25 05:23PM	Dow Jones Futures: Tesla, Nvidia Lead 5 Giants In Buy Areas; Market Strong As 2025 Nears End (Investor's Business Daily)
03:41PM	Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens (Investor's Business Daily)
Dec-22-25 10:19PM	Multiple Analysts Lift Guardant Health, Inc. (GH) Targets on Screening and Data Growth (Insider Monkey)
Dec-16-25 10:41AM	Guardant Health price target raised to $120 from $100 at BofA (TipRanks)
Dec-11-25 08:05AM	Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S. (Business Wire)
Dec-09-25 10:19AM	Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run? (Zacks)
08:05AM	Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy (Business Wire)
Dec-08-25 10:15AM	Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook (Zacks)
Dec-05-25 06:42PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) -5.99%
09:41AM	Tempus AI: Revenue Mix and 2026 Growth Outlook Explained (Zacks)
08:05AM	Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium (Business Wire)
Dec-04-25 09:40AM	Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-03-25 03:27PM	Why Guardant Health (GH) Stock Is Up Today (StockStory)
Nov-24-25 06:40PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) +5.53%
Nov-23-25 11:03PM	Guardant Health (GH): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-20-25 03:45PM	These 15 stocks are still showing momentum - and a market-beating edge (MarketWatch)
01:00PM	The marketing guru who helped turn Khosla Ventures into an AI powerhouse is moving on (TechCrunch)
10:34AM	Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences, Regeneron (The Wall Street Journal)
09:41AM	Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences (The Wall Street Journal)
Nov-14-25 07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks)
Nov-12-25 08:05AM	Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access (Business Wire)
Nov-10-25 08:05AM	Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring (Business Wire)
Nov-07-25 08:00AM	Guardant Health to Participate in Upcoming Investor Conferences (Business Wire)
Nov-06-25 06:35PM	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:05AM	New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response (Business Wire)
07:05AM	Cathie Wood Loads Up Pinterest After Sell-Off -- Dumps Shopify, Roku, and Robinhood (GuruFocus.com)
Nov-05-25 04:05PM	Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients (Business Wire)
12:26PM	Why Guardant Health (GH) Shares Are Sliding Today (StockStory)
02:15AM	Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering (Business Wire)
02:15AM	Guardant Health Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
12:37AM	The Top 5 Analyst Questions From Guardant Health's Q3 Earnings Call (StockStory)
Nov-04-25 04:39PM	Guardant Health Announces Proposed Public Offering of Common Stock (Business Wire)
04:38PM	Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033 (Business Wire)
Oct-31-25 10:01AM	Guardant Health (GH) Jumps to New Record High on Earnings Blowout, Bullish Outlook (Insider Monkey)
05:45AM	Why Guardant Health Was Such an Investor Darling This Week (Motley Fool)
Oct-30-25 07:19PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) +27.87%
06:56PM	Why Guardant Health Stock Surged Today (Motley Fool)
04:13PM	Why IBD 50's Guardant Health, Up 137% in 2025, Just Rocketed Again (Investor's Business Daily)
09:54AM	These Stocks Are Moving the Most Today: Microsoft, Meta, Alphabet, Chipotle, Carvana, FMC, Roblox, Guardant Health, Metsera, and More (Barrons.com)
09:11AM	GH Q3 Deep Dive: Broad-Based Growth, Screening Momentum, and Margin Improvement (StockStory)
Oct-29-25 07:30PM	Guardant Health (GH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:05PM	Guardant Health (GH) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:18PM	Guardant Health's (NASDAQ:GH) Q3: Strong Sales, Stock Jumps 15.5% (StockStory)
05:03PM	Guardant Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance (Business Wire)
Oct-27-25 11:10PM	Earnings To Watch: Guardant Health (GH) Reports Q3 Results Tomorrow (StockStory)
09:20AM	Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals (Zacks)
08:05AM	Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights (Business Wire)
Oct-26-25 03:01PM	Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025 (Business Wire)
Oct-21-25 03:41PM	Colon Cancer Screening Leader Guardant Health Tests Buy Point As Earnings Loom (Investor's Business Daily)
Oct-20-25 04:24PM	Stock Of The Day: Why IBD 50's Guardant Health Has Rallied 231% In A Month (Investor's Business Daily) +7.24%
Oct-18-25 08:00AM	S&P 500's Walmart In Buy Zone, Leads Five Stocks Near Buy Points (Investor's Business Daily)
08:00AM	S&P 500's New AI Play? Walmart In Buy Zone, Leads Five Stocks To Watch Amid Volatile Market (Investor's Business Daily)
04:16AM	Grail Blood Test Found Seven Times More Cancers Than Standard Tests, Data Show (Barrons.com)
Oct-17-25 09:45AM	Tempus AI Fuels Growth Through Strategic Biotech Collaborations (Zacks)
09:35AM	Banks Look To Stabilize After First Brands Bankruptcy Torpedoes Shares (Investor's Business Daily)
08:17AM	Stock Market Today: Dow Falls Amid Bank Fears; Eli Lilly, Novo Sell Off On Trump Comments (Live Coverage) (Investor's Business Daily)
Oct-15-25 04:57PM	Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025 (Business Wire) +5.11%
Oct-09-25 04:05PM	Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025 (Business Wire)
Sep-30-25 12:33PM	Guardant Health, Inc. (GH) Unveils Shield V2, Boosts Early Cancer Detection Accuracy (Insider Monkey)

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krognes Steve E.	Director	Jan 31 '26	Option Exercise	0.00	154	0	18,899	Feb 02 04:30 PM
Monroe Terilyn J.	Chief People Officer	Jan 21 '26	Sale	114.09	8,571	977,902	20,990	Jan 22 05:45 PM
MIGNONE ROBERTO	Director	Jan 21 '26	Option Exercise	0.00	264	0	3,959	Jan 22 05:44 PM
Monroe Terilyn J.	Officer	Jan 21 '26	Proposed Sale	114.09	8,571	977,902		Jan 21 04:10 PM
Hidalgo Medina Manuel	Director	Jan 17 '26	Option Exercise	0.00	232	0	1,261	Jan 20 04:47 PM
Tariq Musa	Director	Jan 15 '26	Option Exercise	0.00	250	0	8,243	Jan 16 04:39 PM
Monroe Terilyn J.	Chief People Officer	Jan 15 '26	Option Exercise	0.00	17,379	0	38,369	Jan 16 04:39 PM
Monroe Terilyn J.	Chief People Officer	Jan 07 '26	Sale	112.08	10,031	1,124,279	20,990	Jan 09 04:09 PM
Monroe Terilyn J.	Officer	Jan 07 '26	Proposed Sale	112.07	10,031	1,124,200		Jan 07 04:03 PM
Saia John G.	Chief Legal Officer	Jan 01 '26	Option Exercise	0.00	19,046	0	62,703	Jan 05 06:01 PM
Monroe Terilyn J.	Chief People Officer	Jan 01 '26	Option Exercise	0.00	17,555	0	38,545	Jan 05 06:01 PM
Kalia Kumud	Chief Information Officer	Jan 01 '26	Option Exercise	0.00	21,237	0	43,916	Jan 05 06:00 PM
Freeman Chris	Chief Commercial Officer	Jan 01 '26	Option Exercise	0.00	27,237	0	54,032	Jan 05 05:59 PM
EAGLE CRAIG	Chief Medical Officer	Jan 01 '26	Option Exercise	0.00	25,442	0	70,449	Jan 05 05:58 PM
Chudova Darya	Chief Technology Officer	Jan 01 '26	Option Exercise	0.00	22,732	0	29,744	Jan 05 05:57 PM
Bell Michael Brian	Chief Financial Officer	Jan 01 '26	Option Exercise	0.00	23,038	0	52,703	Jan 05 05:57 PM
Talasaz AmirAli	Co-Chief Executive Officer	Dec 31 '25	Option Exercise	0.00	4,815	0	2,002,689	Jan 05 05:56 PM
Talasaz AmirAli	Co-Chief Executive Officer	Jan 01 '26	Option Exercise	0.00	23,997	0	2,024,245	Jan 05 05:56 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Dec 31 '25	Option Exercise	0.00	4,815	0	2,051,958	Jan 05 05:55 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Jan 01 '26	Option Exercise	0.00	23,997	0	2,073,514	Jan 05 05:55 PM
Krognes Steve E.	Director	Dec 31 '25	Option Exercise	0.00	154	0	18,745	Jan 05 05:54 PM
MIGNONE ROBERTO	Director	Dec 21 '25	Option Exercise	0.00	264	0	3,695	Dec 23 07:25 PM
Hidalgo Medina Manuel	Director	Dec 17 '25	Option Exercise	0.00	232	0	1,029	Dec 18 06:34 PM
Tariq Musa	Director	Dec 17 '25	Sale	101.46	116	11,769	7,993	Dec 18 06:33 PM
Tariq Musa	Director	Dec 15 '25	Option Exercise	0.00	250	0	8,109	Dec 17 07:21 PM
Saia John G.	Chief Legal Officer	Dec 15 '25	Option Exercise	0.00	1,020	0	44,192	Dec 17 07:20 PM
Kalia Kumud	Chief Information Officer	Dec 15 '25	Option Exercise	0.00	637	0	23,002	Dec 17 07:20 PM
Freeman Chris	Chief Commercial Officer	Dec 15 '25	Option Exercise	0.00	1,402	0	27,389	Dec 17 07:19 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Dec 15 '25	Sale	103.82	90,565	9,402,220	2,047,143	Dec 17 07:18 PM
EAGLE CRAIG	Chief Medical Officer	Dec 15 '25	Option Exercise	0.00	1,402	0	45,718	Dec 17 07:18 PM
Chudova Darya	Chief Technology Officer	Dec 15 '25	Sale	104.04	5,451	567,132	7,012	Dec 17 07:17 PM
Bell Michael Brian	Chief Financial Officer	Dec 15 '25	Option Exercise	0.00	3,272	0	31,324	Dec 17 07:17 PM
Tariq Musa	Director	Dec 17 '25	Proposed Sale	101.46	116	11,769		Dec 17 04:58 PM
Eltoukhy Helmy	Officer	Dec 15 '25	Proposed Sale	103.82	90,565	9,402,223		Dec 15 05:08 PM
Talasaz AmirAli	Co-Chief Executive Officer	Dec 08 '25	Sale	105.05	100,000	10,505,474	168,223	Dec 10 09:33 PM
Kalia Kumud	Chief Information Officer	Dec 08 '25	Sale	104.60	2,000	209,204	22,365	Dec 10 09:32 PM
Hidalgo Medina Manuel	Director	Dec 08 '25	Option Exercise	32.55	1,000	32,550	2,047	Dec 10 09:32 PM
Hidalgo Medina Manuel	Director	Dec 08 '25	Sale	105.00	1,250	131,250	797	Dec 10 09:32 PM
Chudova Darya	Chief Technology Officer	Dec 08 '25	Sale	105.04	13,664	1,435,227	54,480	Dec 10 09:31 PM
Chudova Darya	Chief Technology Officer	Dec 08 '25	Sale	106.00	9,271	982,753	12,463	Dec 10 09:31 PM
Freeman Chris	Chief Commercial Officer	Dec 05 '25	Sale	103.07	31,452	3,241,621	25,987	Dec 08 09:37 PM
Bell Michael Brian	Chief Financial Officer	Dec 05 '25	Option Exercise	30.71	56,287	1,728,787	108,414	Dec 08 09:37 PM
Bell Michael Brian	Chief Financial Officer	Dec 05 '25	Sale	103.14	80,362	8,288,742	28,052	Dec 08 09:37 PM
CLARK IAN T	Director	Dec 05 '25	Option Exercise	35.83	28,611	1,025,156	38,462	Dec 08 09:36 PM
CLARK IAN T	Director	Dec 05 '25	Sale	107.19	28,611	3,066,817	9,851	Dec 08 09:36 PM
Talasaz AmirAli	Officer	Dec 08 '25	Proposed Sale	105.05	100,000	10,505,470		Dec 08 05:50 PM
Chudova Darya	Officer	Dec 08 '25	Proposed Sale	105.43	28,780	3,034,203		Dec 08 04:47 PM
Hidalgo Medina Manuel	Director	Dec 08 '25	Proposed Sale	105.00	1,250	131,250		Dec 08 04:46 PM
Kalia Kumud	Officer	Dec 08 '25	Proposed Sale	104.60	2,000	209,204		Dec 08 04:44 PM
Freeman Chris	Officer	Dec 05 '25	Proposed Sale	103.07	31,452	3,241,621		Dec 05 05:22 PM
CLARK IAN T	Director	Dec 05 '25	Proposed Sale	107.19	28,611	3,066,818		Dec 05 05:21 PM
Bell Michael Brian	Officer	Dec 05 '25	Proposed Sale	103.14	80,362	8,288,741		Dec 05 05:20 PM
Monroe Terilyn J.	Chief People Officer	Dec 01 '25	Option Exercise	22.68	50,000	1,134,050	76,087	Dec 03 09:30 PM
Monroe Terilyn J.	Chief People Officer	Dec 01 '25	Sale	105.97	55,167	5,846,163	20,920	Dec 03 09:30 PM
Krognes Steve E.	Director	Nov 30 '25	Option Exercise	0.00	155	0	18,591	Dec 01 09:41 PM
Monroe Terilyn J.	Officer	Dec 01 '25	Proposed Sale	105.97	55,167	5,846,164		Dec 01 04:56 PM
MIGNONE ROBERTO	Director	Nov 21 '25	Option Exercise	0.00	264	0	3,431	Nov 24 06:21 PM
Tariq Musa	Director	Nov 19 '25	Sale	96.25	116	11,165	7,859	Nov 20 09:27 PM
Tariq Musa	Director	Nov 19 '25	Proposed Sale	96.25	116	11,165		Nov 19 04:01 PM
Hidalgo Medina Manuel	Director	Nov 17 '25	Option Exercise	0.00	232	0	1,047	Nov 18 05:07 PM
Tariq Musa	Director	Nov 15 '25	Option Exercise	0.00	250	0	7,975	Nov 17 05:30 PM
Hidalgo Medina Manuel	Director	Nov 07 '25	Option Exercise	32.55	1,000	32,550	2,315	Nov 10 07:18 PM
Hidalgo Medina Manuel	Director	Nov 07 '25	Sale	95.19	1,500	142,780	815	Nov 10 07:18 PM
Saia John G.	Chief Legal Officer	Nov 07 '25	Sale	96.25	8,996	865,865	43,172	Nov 10 07:17 PM
Hidalgo Medina Manuel	Director	Nov 07 '25	Proposed Sale	95.19	1,500	142,780		Nov 07 04:25 PM
Saia John G.	Officer	Nov 07 '25	Proposed Sale	96.25	8,996	865,865		Nov 07 04:21 PM
Krognes Steve E.	Director	Oct 31 '25	Option Exercise	0.00	154	0	18,436	Nov 03 05:45 PM
MIGNONE ROBERTO	Director	Oct 21 '25	Option Exercise	0.00	3,167	0	3,167	Oct 22 07:07 PM
Hidalgo Medina Manuel	Director	Oct 17 '25	Option Exercise	0.00	232	0	1,315	Oct 20 07:50 PM
Tariq Musa	Director	Oct 17 '25	Sale	66.95	116	7,766	7,725	Oct 20 07:49 PM
POTTER MYRTLE S	Director	Oct 17 '25	Sale	66.95	26	1,741	18,324	Oct 20 07:48 PM
Tariq Musa	Director	Oct 17 '25	Proposed Sale	66.95	116	7,766		Oct 17 04:02 PM
POTTER MYRTLE S	Director	Oct 17 '25	Proposed Sale	66.96	26	1,741		Oct 17 04:00 PM
Tariq Musa	Director	Oct 15 '25	Option Exercise	0.00	250	0	7,841	Oct 16 09:13 PM
POTTER MYRTLE S	Director	Oct 15 '25	Option Exercise	0.00	69	0	18,350	Oct 16 09:11 PM
Saia John G.	Chief Legal Officer	Oct 01 '25	Option Exercise	0.00	14,167	0	59,599	Oct 02 08:06 PM
Monroe Terilyn J.	Chief People Officer	Oct 01 '25	Option Exercise	0.00	10,477	0	31,397	Oct 02 08:05 PM
Kalia Kumud	Chief Information Officer	Oct 01 '25	Option Exercise	0.00	10,549	0	29,713	Oct 02 08:05 PM
Freeman Chris	Chief Commercial Officer	Oct 01 '25	Option Exercise	0.00	13,550	0	63,179	Oct 02 08:05 PM
EAGLE CRAIG	Chief Medical Officer	Oct 01 '25	Option Exercise	0.00	13,859	0	51,341	Oct 02 08:04 PM
Chudova Darya	Chief Technology Officer	Oct 01 '25	Option Exercise	0.00	16,104	0	97,553	Oct 02 08:04 PM
Bell Michael Brian	Chief Financial Officer	Oct 01 '25	Option Exercise	0.00	15,181	0	59,822	Oct 02 08:04 PM
Talasaz AmirAli	Co-Chief Executive Officer	Sep 30 '25	Option Exercise	0.00	4,814	0	1,988,479	Oct 02 08:03 PM
Talasaz AmirAli	Co-Chief Executive Officer	Oct 01 '25	Option Exercise	0.00	23,997	0	2,010,036	Oct 02 08:03 PM
Krognes Steve E.	Director	Sep 30 '25	Option Exercise	0.00	154	0	18,282	Oct 02 08:03 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Sep 30 '25	Option Exercise	0.00	4,814	0	2,128,313	Oct 02 08:01 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Oct 01 '25	Option Exercise	0.00	23,997	0	2,149,870	Oct 02 08:01 PM
Hidalgo Medina Manuel	Director	Sep 17 '25	Option Exercise	0.00	232	0	1,083	Sep 18 04:33 PM
Tariq Musa	Director	Sep 15 '25	Option Exercise	0.00	249	0	7,707	Sep 17 05:17 PM
Tariq Musa	Director	Sep 17 '25	Sale	55.63	116	6,453	7,591	Sep 17 05:17 PM
POTTER MYRTLE S	Director	Sep 15 '25	Option Exercise	0.00	68	0	18,307	Sep 17 05:17 PM
POTTER MYRTLE S	Director	Sep 17 '25	Sale	55.63	26	1,446	18,281	Sep 17 05:17 PM
Saia John G.	Chief Legal Officer	Sep 15 '25	Option Exercise	0.00	1,019	0	45,967	Sep 17 05:16 PM
Kalia Kumud	Chief Information Officer	Sep 15 '25	Option Exercise	0.00	638	0	19,488	Sep 17 05:15 PM
Freeman Chris	Chief Commercial Officer	Sep 15 '25	Option Exercise	0.00	1,402	0	50,223	Sep 17 05:15 PM
EAGLE CRAIG	Chief Medical Officer	Sep 15 '25	Option Exercise	0.00	1,402	0	38,193	Sep 17 05:14 PM
Bell Michael Brian	Chief Financial Officer	Sep 15 '25	Option Exercise	0.00	3,272	0	46,300	Sep 17 05:13 PM
POTTER MYRTLE S	Director	Sep 17 '25	Proposed Sale	55.62	26	1,446		Sep 17 04:17 PM
Tariq Musa	Director	Sep 17 '25	Proposed Sale	55.63	116	6,453		Sep 17 04:16 PM
Hidalgo Medina Manuel	Director	Sep 12 '25	Sale	54.16	2,165	117,251	851	Sep 15 05:09 PM

Open in Screener

XGN

Exagen Inc

Feb 17 • 01:45PM ET

3.28

+0.00 0.03 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN ONC MYGN QGEN NTRA GH VCYT CDNA PRPO FLGT

| Held by: VTI VXF IWC ROSC DFAS DFAC DFSU DCOR

Index	-	P/E	-	EPS (ttm)	-0.93	Insider Own	36.09%	Shs Outstand	22.51M	Perf Week	-2.64%
Market Cap	74.35M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	-0.63%	Shs Float	14.48M	Perf Month	-32.07%
Enterprise Value	66.87M	PEG	-	EPS next Q	-0.20	Inst Own	50.36%	Short Float	4.05%	Perf Quarter	-64.91%
Income	-19.04M	P/S	1.17	EPS this Y	-7.81%	Inst Trans	9.61%	Short Ratio	1.25	Perf Half Y	-65.43%
Sales	63.60M	P/B	4.07	EPS next Y	40.66%	ROA	-35.78%	Short Interest	0.59M	Perf YTD	-46.04%
Book/sh	0.81	P/C	2.09	EPS next 5Y	32.34%	ROE	-122.81%	52W High	12.23 -73.17%	Perf Year	-22.43%
Cash/sh	1.57	P/FCF	-	EPS past 3/5Y	20.95% 19.20%	ROIC	-43.97%	52W Low	2.67 22.88%	Perf 3Y	26.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.83% 6.62%	Gross Margin	59.86%	Volatility	6.93% 8.12%	Perf 5Y	-82.08%
Dividend TTM	-	EV/Sales	1.05	EPS Y/Y TTM	1.34%	Oper. Margin	-19.62%	ATR (14)	0.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.81	Sales Y/Y TTM	14.08%	Profit Margin	-29.94%	RSI (14)	24.24	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.08	EPS Q/Q	-12.16%	SMA20	-15.07%	Beta	1.90	Target Price	12.57
Payout	-	Debt/Eq	1.55	Sales Q/Q	37.87%	SMA50	-38.37%	Rel Volume	0.34	Prev Close	3.28
Employees	209	LT Debt/Eq	1.39	Earnings	Nov 04 BMO	SMA200	-58.02%	Avg Volume	467.65K	Price	3.28
IPO	Sep 19, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-97.58% 2.14%	Trades		Volume	105,440	Change	0.03%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-11-25	Initiated	B. Riley Securities	Buy	$15
Jul-30-25	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$12
Jul-23-25	Initiated	Craig Hallum	Buy	$12
Aug-05-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Oct-15-21	Resumed	Cowen	Outperform	$26
Apr-15-21	Initiated	Canaccord Genuity	Buy	$25
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$32
Oct-08-20	Initiated	BTIG Research	Buy	$18
Jun-02-20	Resumed	Cantor Fitzgerald	Overweight	$19 → $20
Oct-14-19	Initiated	William Blair	Outperform
Oct-14-19	Initiated	Cowen	Outperform	$17
Oct-14-19	Initiated	Cantor Fitzgerald	Overweight	$18

Show Previous Ratings

Jan-11-26 03:00PM	Exagen Inc. Announces Select Preliminary 2025 Financial Results (GlobeNewswire)
Nov-11-25 09:00AM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
Nov-04-25 04:08PM	Exagen Inc (XGN) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansion ... (GuruFocus.com) -8.96%
09:10AM	Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Q3 2025 Results (GlobeNewswire)
08:06AM	Loading…
Nov-03-25 08:06AM	What To Expect From Exagen Inc (XGN) Q3 2025 Earnings (GuruFocus.com)
Oct-23-25 09:15AM	Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence (GlobeNewswire)
Oct-21-25 04:05PM	Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Aug-12-25 10:30PM	[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-06-25 04:05PM	Exagen Inc. to Participate in Third Quarter Investor Conferences (GlobeNewswire)
Jul-29-25 09:10AM	Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +14.34%
08:00AM	Exagen Inc. Reports Strong Q2 2025 Results (GlobeNewswire)
Jul-28-25 09:39AM	Exagen Inc (XGN) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-24-25 09:09AM	Exagen Inc. (XGN): A Bull Case Theory (Insider Monkey)
08:45AM	Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
04:05PM	Loading…
Jul-17-25 04:05PM	Exagen Inc. Appoints Chas McKhann to Board of Directors (GlobeNewswire)
Jul-15-25 04:05PM	Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 (GlobeNewswire)
Jun-23-25 09:00AM	Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics (GlobeNewswire)
May-09-25 04:05PM	Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares (GlobeNewswire) -7.31%
May-08-25 08:30AM	Exagen Inc. Prices Public Offering of Common Stock (GlobeNewswire) -9.81%
May-07-25 04:05PM	Exagen Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +6.39%
May-06-25 03:03AM	Exagen Inc (XGN) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic Wins Amidst ... (GuruFocus.com)
01:18AM	Q1 2025 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 04:51PM	Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:10AM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume (GlobeNewswire)
May-02-25 09:36AM	Exagen Inc (XGN) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-28-25 09:00AM	Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors (GlobeNewswire) +7.09%
Apr-26-25 03:31AM	Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability (Seeking Alpha)
Apr-21-25 04:05PM	Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025 (GlobeNewswire) +9.26%
03:04AM	Loading…
Mar-12-25 03:04AM	Exagen Inc (XGN) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives (GuruFocus.com)
12:10AM	Q4 2024 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-25 09:15AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +18.25%
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights (GlobeNewswire)
Feb-25-25 04:05PM	Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025 (GlobeNewswire)
Feb-05-25 06:38AM	Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength? (Zacks) +6.18%
Feb-04-25 04:05PM	Exagen Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire) +29.38%
Jan-12-25 12:00PM	Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results (GlobeNewswire)
Dec-12-24 09:00AM	Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE CTD (GlobeNewswire) +12.02%
Nov-14-24 04:30PM	Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE CTD Platform (GlobeNewswire) +5.45%
Nov-13-24 04:05PM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
02:09AM	Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... (GuruFocus.com)
12:51AM	Q3 2024 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 09:25AM	Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.06%
Nov-11-24 07:25AM	Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:05PM	Exagen to Announce Third Quarter 2024 Results on November 12, 2024 (GlobeNewswire)
Oct-21-24 04:05PM	Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence (GlobeNewswire)
Sep-04-24 04:05PM	Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire) +15.93%
Aug-29-24 09:55AM	Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now (Zacks)
Aug-26-24 08:50AM	Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Aug-09-24 09:15AM	Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? (Zacks) +22.46%
Aug-08-24 08:50AM	Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain (Zacks) +12.65%
Aug-05-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +17.65%
09:10AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance (GlobeNewswire)
Aug-02-24 09:00AM	Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 09:00AM	Exagen Appoints Jeffrey G. Black as New Chief Financial Officer (GlobeNewswire)
Jul-22-24 09:00AM	Exagen to Announce Second Quarter 2024 Results on August 5, 2024 (GlobeNewswire)
Jun-13-24 08:50AM	Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors (Zacks)
May-15-24 05:01AM	Exagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ... (GuruFocus.com) +8.52%
May-13-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:10AM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year (GlobeNewswire)
May-06-24 04:05PM	Exagen Announces Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-30-24 04:05PM	Exagen to Announce First Quarter 2024 Results on May 13, 2024 (GlobeNewswire)
Apr-26-24 08:30AM	Exagen Inc. Announces Changes to the Board of Directors (GlobeNewswire)
Mar-19-24 09:37AM	Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript (Insider Monkey) -12.99%
01:55AM	Q4 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 12:52PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +9.26%
09:25AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Mar-08-24 09:00AM	Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire)
Mar-07-24 04:05PM	Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024 (GlobeNewswire)
Feb-06-24 08:50AM	Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock (Zacks)
Jan-30-24 04:05PM	Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire) -6.52%
Jan-07-24 12:00PM	Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance (GlobeNewswire)
Nov-13-23 04:05PM	Exagen Inc. Reports Strong Third Quarter 2023 Results (GlobeNewswire) +16.44%
Nov-09-23 04:05PM	Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers (GlobeNewswire) -6.25%
Nov-02-23 04:05PM	Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Oct-30-23 04:05PM	Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023 (GlobeNewswire) +6.75% +6.08%
Sep-28-23 04:05PM	Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting (GlobeNewswire)
Sep-12-23 04:05PM	Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-09-23 10:47AM	Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call Transcript (Insider Monkey) -7.22%
Aug-08-23 04:13AM	Q2 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 09:15AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.76%
08:00AM	Exagen Inc. Reports Strong Second Quarter 2023 Results (GlobeNewswire)
Jul-26-23 04:05PM	Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-25-23 04:05PM	Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023 (GlobeNewswire) -6.51%
Jul-24-23 04:05PM	Exagen Inc. Appoints Paul Kim to Board of Directors (GlobeNewswire)
07:33AM	This Exagen Insider Increased Their Holding In The Last Year (Simply Wall St.)
Jun-13-23 08:19AM	Exagen Inc.'s (NASDAQ:XGN) Low P/S No Reason For Excitement (Simply Wall St.) -8.36%
May-30-23 09:00AM	Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference (GlobeNewswire)
May-17-23 07:11AM	Exagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three years (Simply Wall St.) -6.90%
May-16-23 11:03AM	Q1 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents) +19.51%
May-15-23 05:55PM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Exagen Inc. Reports First Quarter 2023 Results (GlobeNewswire)
May-01-23 04:05PM	Exagen Announces Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-24-23 04:05PM	Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023 (GlobeNewswire)
Mar-24-23 08:16AM	Exagen Inc. (NASDAQ:XGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 06:12AM	Exagen Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ABALLI JOHN	President and CEO	Oct 16 '25	Sale	11.82	31,787	375,598	714,427	Oct 20 05:20 PM
Black Jeffrey G.	Chief Financial Officer	Sep 02 '25	Sale	9.79	20,466	200,362	269,026	Sep 04 07:40 PM
NMSIC Co-Investment Fund, L.P.	10% Owner	Mar 25 '25	Sale	3.30	350,000	1,155,000	1,758,958	Mar 27 04:15 PM

Open in Screener

PSNL

Personalis Inc

Feb 17 • 01:45PM ET

8.76

+0.55 6.70 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN NTRA CDNA GH FLGT BNR EXAS FATE TXG MYGN

| Held by: ARKG VTI IWM VXF IWN IBB VTWO DFAS VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-0.88	Insider Own	40.23%	Shs Outstand	88.75M	Perf Week	11.88%
Market Cap	777.92M	Forward P/E	-	EPS next Y	-0.97	Insider Trans	0.52%	Shs Float	53.08M	Perf Month	-8.84%
Enterprise Value	669.28M	PEG	-	EPS next Q	-0.29	Inst Own	56.91%	Short Float	16.60%	Perf Quarter	15.26%
Income	-73.88M	P/S	11.26	EPS this Y	31.49%	Inst Trans	12.72%	Short Ratio	6.23	Perf Half Y	90.43%
Sales	69.10M	P/B	4.54	EPS next Y	-3.67%	ROA	-30.61%	Short Interest	8.81M	Perf YTD	10.05%
Book/sh	1.93	P/C	5.17	EPS next 5Y	16.92%	ROE	-43.69%	52W High	11.50 -23.83%	Perf Year	58.98%
Cash/sh	1.69	P/FCF	-	EPS past 3/5Y	2.63% -11.31%	ROIC	-36.06%	52W Low	2.83 209.96%	Perf 3Y	160.71%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-0.34% 5.35%	Gross Margin	26.67%	Volatility	8.56% 9.42%	Perf 5Y	-78.01%
Dividend TTM	-	EV/Sales	9.69	EPS Y/Y TTM	47.74%	Oper. Margin	-117.08%	ATR (14)	0.81	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.69	Sales Y/Y TTM	-21.02%	Profit Margin	-106.92%	RSI (14)	49.10	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	4.80	EPS Q/Q	61.88%	SMA20	-4.53%	Beta	2.04	Target Price	11.29
Payout	-	Debt/Eq	0.24	Sales Q/Q	-43.62%	SMA50	-1.61%	Rel Volume	0.80	Prev Close	8.21
Employees	229	LT Debt/Eq	0.20	Earnings	Feb 26 AMC	SMA200	23.32%	Avg Volume	1.41M	Price	8.76
IPO	Jun 20, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.04% 5.79%	Trades		Volume	762,463	Change	6.70%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight	$11
May-15-25	Initiated	Guggenheim	Buy	$6
Mar-17-25	Initiated	Craig Hallum	Buy	$8
Feb-06-23	Upgrade	Needham	Hold → Buy	$8
Feb-06-23	Upgrade	Needham	Hold → Buy
Jan-07-22	Upgrade	BofA Securities	Neutral → Buy	$27 → $23
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-03-21	Downgrade	Needham	Buy → Hold
Oct-15-21	Resumed	Cowen	Outperform
Sep-20-21	Reiterated	Needham	Buy	$33 → $28
May-06-21	Upgrade	Oppenheimer	Perform → Outperform	$28
Jan-28-21	Initiated	Truist	Buy	$50
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral	$40
Nov-12-20	Reiterated	Needham	Buy	$25 → $32
Nov-06-20	Downgrade	Oppenheimer	Outperform → Perform
Oct-19-20	Initiated	Citigroup	Buy	$35
Oct-08-20	Initiated	BTIG Research	Buy	$35
Aug-27-20	Initiated	H.C. Wainwright	Buy	$30
Aug-18-20	Initiated	Needham	Buy	$25
Sep-26-19	Upgrade	BofA/Merrill	Neutral → Buy	$22

Show Previous Ratings

Feb-12-26 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results (Business Wire) -5.73%
Feb-10-26 09:18AM	Personalis Gets Medicare Coverage For Lung Cancer Surveillance Test (Benzinga) +10.09%
06:00AM	Personalis Receives Medicare Coverage for NeXT Personal in Lung Cancer Surveillance (Business Wire)
Feb-03-26 05:20PM	AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit (Motley Fool) -9.67%
Feb-02-26 08:18PM	Personalis, Inc. (PSNL): A Bull Case Theory (Insider Monkey)
06:00AM	Loading…
06:00AM	Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors (Business Wire)
Jan-28-26 04:01PM	Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire)
Jan-19-26 01:27PM	Cathie Wood Buys AI Chips, Sells Tesla (GuruFocus.com)
Jan-12-26 04:00PM	Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker (Business Wire) +5.80%
Jan-08-26 08:00AM	Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights (Business Wire) -10.43%
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-30-25 12:19PM	Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) (Insider Monkey)
Dec-17-25 06:00AM	Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors (Business Wire)
Dec-11-25 09:00AM	New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer (Business Wire)
Nov-18-25 04:01PM	Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference (Business Wire) +8.14%
12:11AM	Loading…
Nov-05-25 12:11AM	Personalis Inc (PSNL) Q3 2025 Earnings Call Highlights: Strong Clinical Adoption Amid Revenue ... (GuruFocus.com) -12.26%
Nov-04-25 05:30PM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:27PM	Personalis: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 07:51AM	Earnings To Watch: Personalis Inc (PSNL) Reports Q3 2025 Result (GuruFocus.com) -6.64%
Oct-21-25 04:01PM	Personalis to Announce Third Quarter 2025 Financial Results (Business Wire) -5.43% -6.74%
Oct-17-25 03:14AM	Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last? (Zacks) -11.19%
Oct-16-25 09:00AM	Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing (Business Wire) +20.52%
Sep-15-25 05:35PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks) +13.17%
Sep-10-25 04:05PM	CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test (Business Wire)
Sep-03-25 04:05PM	Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing (Business Wire)
Aug-27-25 04:01PM	Personalis to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-25 09:35AM	Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL) (Zacks) +5.69%
Aug-12-25 09:35AM	After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL) (Zacks)
12:00PM	Loading…
Aug-08-25 12:00PM	All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy (Zacks)
06:00AM	Tempus Reports Second Quarter 2025 Results (Business Wire)
Aug-05-25 04:10PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance) -21.90%
04:01PM	Personalis Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-04-25 09:58AM	Earnings To Watch: Personalis Inc (PSNL) Reports Q2 2025 Result (GuruFocus.com)
Jul-22-25 04:01PM	Personalis to Announce Second Quarter 2025 Financial Results (Business Wire) +5.13%
Jul-18-25 04:00PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-16-25 06:35PM	From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine (PR Newswire)
Jul-09-25 04:00PM	Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients (Business Wire)
Jul-03-25 07:08AM	Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Jun-17-25 10:40AM	Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-13-25 12:07PM	Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach (Zacks)
Jun-03-25 04:00PM	Personalis' NeXT Personal Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO (Business Wire) +5.53%
Jun-02-25 04:00PM	New Data Shows NeXT Personal Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse (Business Wire)
May-22-25 06:00AM	Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection (Business Wire)
May-14-25 04:01PM	Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference (Business Wire) -6.23%
May-07-25 03:23AM	Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com) +21.00%
May-06-25 05:55PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.10%
04:01PM	Personalis Reports First Quarter 2025 Financial Results (Business Wire)
May-05-25 10:12AM	Personalis Inc (PSNL) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-30-25 08:05PM	Bausch Health (BHC) Q1 Earnings and Revenues Lag Estimates (Zacks)
Apr-28-25 05:00PM	Personalis' NeXT Personal Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study (Business Wire)
Apr-22-25 06:47PM	Is Personalis, Inc. (PSNL) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey) +7.91% +7.92%
04:01PM	Personalis to Announce First Quarter 2025 Financial Results (Business Wire)
06:00AM	Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection (Business Wire)
Apr-17-25 04:15PM	The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. (Investor's Business Daily)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-26-25 04:01PM	Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-03-25 06:00AM	New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection (Business Wire)
Feb-28-25 04:00AM	Personalis Inc (PSNL) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Feb-27-25 05:20PM	Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.36%
04:21PM	Personalis: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-26-25 08:09AM	Personalis Inc (PSNL) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com) +5.91%
Feb-20-25 10:00AM	Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -6.78%
Feb-18-25 04:01PM	Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference (Business Wire) +9.62%
Feb-13-25 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results (Business Wire) +7.08% +10.42%
Jan-28-25 04:01PM	Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire) -6.37% -7.90%
Jan-20-25 12:00PM	Personalis (PSNL) Upgraded to Buy: Here's Why (Zacks)
Jan-13-25 11:09AM	Researchers find ctDNA test predicts lung cancer outcomes in study (Medical Device Network)
05:00AM	New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer (Business Wire)
Jan-07-25 04:01PM	Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue (Business Wire) -6.71% -6.35%
Dec-21-24 07:30AM	Personalis price target raised to $8 from $7 at BTIG (TipRanks)
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) +9.32%
Dec-19-24 09:00AM	Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna (Business Wire) +47.75%
Dec-18-24 03:00AM	Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma (Insider Monkey) -7.29%
Dec-16-24 08:00AM	Personalis and Tempus Expand Collaboration to Biopharma (Business Wire)
Nov-20-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire) -6.23%
Nov-07-24 10:01AM	Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ... (GuruFocus.com) -22.58%
Nov-06-24 05:25PM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Personalis: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-05-24 04:01PM	Personalis to Present at the Stifel 2024 Healthcare Conference (Business Wire) +12.80%
08:01AM	Personalis Inc (PSNL) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-23-24 04:01PM	Personalis to Announce Third Quarter 2024 Financial Results (Business Wire)
Sep-16-24 09:00AM	ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal MRD Test (Business Wire)
Aug-22-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire) -9.94%
Aug-21-24 06:13PM	Why Tempus AI Stock Skyrocketed Nearly 22% Today (Motley Fool) +11.42%
Aug-19-24 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-16-24 08:30AM	Personalis and Tempus Announce Expanded Collaboration (Business Wire) +18.15%
Aug-13-24 09:15AM	Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue? (Zacks) +8.12%
Aug-07-24 05:30PM	Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -10.00% +19.10%
04:35PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-06-24 04:05PM	Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% (GlobeNewswire)
Jul-31-24 04:01PM	Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference (Business Wire) +10.58%
Jul-24-24 04:01PM	Personalis to Announce Second Quarter 2024 Financial Results (Business Wire)
Jul-11-24 09:00AM	Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing (GlobeNewswire) +9.68%
Jun-18-24 04:01PM	Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference (Business Wire)
Jun-13-24 08:00AM	Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call (Business Wire)

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tempus AI, Inc.	10% Owner	Nov 18 '25	Buy	7.67	64,750	496,632	12,783,550	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 25 '25	Buy	10.62	23,600	250,665	12,918,346	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 22 '25	Buy	8.93	28,000	250,040	13,039,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 21 '25	Buy	9.40	26,499	249,190	12,869,521	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 24 '25	Buy	9.87	25,225	248,971	12,894,746	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 19 '25	Buy	8.12	30,645	248,837	12,814,195	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 20 '25	Buy	8.63	28,827	248,777	12,843,022	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 17 '25	Buy	7.86	31,650	248,769	12,949,996	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 19 '25	Buy	8.39	29,641	248,688	13,011,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 18 '25	Buy	7.91	31,430	248,611	12,981,426	Feb 13 05:24 PM
Tachibana Aaron	CFO AND COO	Jan 22 '26	Option Exercise	9.16	1,201	11,001	165,659	Jan 23 06:03 PM
Tachibana Aaron	CFO AND COO	Jan 22 '26	Sale	11.50	1,201	13,812	164,458	Jan 23 06:03 PM
AARON L TACHIBANA	Officer	Jan 22 '26	Proposed Sale	9.65	40,000	386,000		Jan 22 04:34 PM
Tachibana Aaron	CFO AND COO	Nov 25 '25	Option Exercise	9.16	103,668	949,599	268,126	Nov 28 05:09 PM
Tachibana Aaron	CFO AND COO	Nov 25 '25	Sale	10.78	103,668	1,117,541	164,458	Nov 28 05:09 PM
AARON L TACHIBANA	Officer	Nov 25 '25	Proposed Sale	9.99	103,668	1,035,643		Nov 25 04:51 PM
Hall Christopher M	PRESIDENT AND CEO	Nov 03 '25	Sale	8.99	29,612	266,212	148,486	Nov 05 04:05 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jul 28 '25	Sale	6.57	452	2,970	124,505	Jul 30 04:20 PM
Tachibana Aaron	CFO AND COO	Jul 28 '25	Sale	6.57	641	4,211	164,458	Jul 30 04:20 PM
Tachibana Aaron	CFO AND COO	May 16 '25	Sale	4.95	1,291	6,390	165,099	May 20 05:53 PM
Moore Stephen Michael	SVP and Chief Legal Officer	May 16 '25	Sale	4.95	1,675	8,291	64,200	May 20 05:51 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	May 16 '25	Sale	4.95	910	4,504	124,957	May 20 05:50 PM

Open in Screener

DGX

Quest Diagnostics, Inc

Feb 17 • 01:45PM ET

204.43

-2.44 -1.18 %

Healthcare • Diagnostics & Research • USA • NYSE

DGX Quest Diagnostics, Inc daily Stock Chart

Peers: LH NEO EXAS OPK NTRA PMD

| Held by: VTI VOO VO IVV SPY VTV RSP XLV VOE VIG

Index	S&P 500	P/E	23.35	EPS (ttm)	8.76	Insider Own	0.46%	Shs Outstand	111.24M	Perf Week	6.89%
Market Cap	22.74B	Forward P/E	17.80	EPS next Y	11.48	Insider Trans	-17.51%	Shs Float	110.73M	Perf Month	7.45%
Enterprise Value	28.82B	PEG	2.15	EPS next Q	2.38	Inst Own	97.25%	Short Float	5.26%	Perf Quarter	8.98%
Income	988.00M	P/S	2.06	EPS this Y	8.03%	Inst Trans	0.41%	Short Ratio	5.39	Perf Half Y	13.72%
Sales	11.04B	P/B	3.14	EPS next Y	7.91%	ROA	6.10%	Short Interest	5.82M	Perf YTD	17.81%
Book/sh	65.18	P/C	54.15	EPS next 5Y	8.28%	ROE	14.17%	52W High	213.20 -4.11%	Perf Year	21.13%
Cash/sh	3.78	P/FCF	16.73	EPS past 3/5Y	3.11% -3.62%	ROIC	7.67%	52W Low	157.20 30.05%	Perf 3Y	37.93%
Dividend Est.	4.36 (2.13%)	EV/EBITDA	13.26	Sales past 3/5Y	3.74% 3.18%	Gross Margin	36.11%	Volatility	3.95% 2.43%	Perf 5Y	67.77%
Dividend TTM	3.20 (1.57%)	EV/Sales	2.61	EPS Y/Y TTM	13.81%	Oper. Margin	14.53%	ATR (14)	5.08	Perf 10Y	216.61%
Dividend Ex-Date	Apr 06, 2026	Quick Ratio	0.96	Sales Y/Y TTM	11.78%	Profit Margin	8.95%	RSI (14)	68.48	Recom	2.21
Dividend Gr. 3/5Y	6.62% 7.39%	Current Ratio	1.04	EPS Q/Q	11.97%	SMA20	6.97%	Beta	0.65	Target Price	219.60
Payout	36.57%	Debt/Eq	0.89	Sales Q/Q	7.06%	SMA50	11.15%	Rel Volume	0.60	Prev Close	206.87
Employees	56000	LT Debt/Eq	0.80	Earnings	Feb 10 BMO	SMA200	13.45%	Avg Volume	1.08M	Price	204.43
IPO	Dec 17, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.42% 1.88%	Trades		Volume	431,712	Change	-1.18%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Upgrade	Barclays	Equal Weight → Overweight	$210
Aug-25-25	Downgrade	Robert W. Baird	Outperform → Neutral	$194
Apr-02-25	Initiated	Redburn Atlantic	Buy	$195
Mar-04-25	Downgrade	Citigroup	Buy → Neutral	$185
Jan-06-25	Upgrade	Leerink Partners	Market Perform → Outperform	$169 → $174
Dec-17-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$145 → $172
Dec-10-24	Resumed	Jefferies	Buy	$175 → $185
Oct-23-24	Upgrade	Robert W. Baird	Neutral → Outperform	$157 → $182
Aug-28-24	Resumed	Evercore ISI	In-line	$165
Jul-10-24	Upgrade	Citigroup	Neutral → Buy	$145 → $165
Feb-26-24	Initiated	Leerink Partners	Market Perform	$135
Feb-07-24	Upgrade	Jefferies	Hold → Buy	$140 → $155
Jan-03-24	Initiated	Barclays	Equal Weight	$145
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy	$140 → $160
Jun-29-23	Initiated	Piper Sandler	Neutral
May-02-23	Downgrade	BofA Securities	Buy → Neutral	$166 → $148
Apr-03-23	Upgrade	Citigroup	Sell → Neutral	$125 → $142
Jan-23-23	Initiated	Evercore ISI	In-line	$159
Nov-17-22	Downgrade	Citigroup	Neutral → Sell	$145 → $125
Aug-22-22	Resumed	Morgan Stanley	Equal-Weight	$142

Show Previous Ratings

Today 12:32AM	5 Insightful Analyst Questions From Quest's Q4 Earnings Call (StockStory)
Feb-11-26 09:15AM	Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? (Zacks)
12:32AM	DGX Q4 Deep Dive: Consumer Testing and Advanced Diagnostics Fuel Growth Amid Margin Headwinds (StockStory)
Feb-10-26 10:07PM	Quest Diagnostics Q4 Earnings Call Highlights (MarketBeat) +7.37%
05:45PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
05:08PM	Loading…
05:08PM	Quest Diagnostics CEO: Chronic Care Disease Management a Big Driver (Bloomberg)
04:02PM	Quest Diagnostics Inc (DGX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
03:30PM	Why Is Quest (DGX) Stock Soaring Today (StockStory)
02:54PM	Stock Market Today: Dow Weakens After Hitting A High; Medical Name Breaks Out (Live Coverage) (Investor's Business Daily)
02:05PM	Quest Diagnostics Stock Smashes 52-Week High On Strong Quarter, Dividend Hike (Benzinga)
10:43AM	Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up (Zacks)
09:50AM	Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock (Zacks)
07:55AM	Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates (Zacks)
07:13AM	Quest Diagnostics Guides FY26 Above Estimates; Boosts Dividend 7.5% - Update (RTT News)
07:06AM	Quest Diagnostics: Q4 Earnings Snapshot (Associated Press Finance)
06:58AM	Loading…
06:58AM	Quest's (NYSE:DGX) Q4 CY2025: Beats On Revenue (StockStory)
06:47AM	Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share (PR Newswire)
06:33AM	Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization (PR Newswire)
Feb-09-26 02:08PM	MedTech Stocks to Report Earnings on Feb. 10: DGX, ZBH & EW (Zacks)
Feb-08-26 10:04PM	Quest (DGX) Q4 Earnings: What To Expect (StockStory)
Feb-06-26 09:45AM	Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term (Zacks)
09:45AM	Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings (Zacks)
Feb-05-26 09:40AM	Here's Why Quest Diagnostics (DGX) is a Strong Value Stock (Zacks)
Feb-04-26 09:40AM	Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-03-26 10:23AM	DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand (Zacks)
Feb-02-26 08:52AM	Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease (PR Newswire)
Jan-30-26 09:54AM	Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly)
Jan-26-26 09:40AM	How TEM Is Capitalizing on AI-Driven Pathology Market Growth (Zacks)
Jan-21-26 02:35PM	Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year (PR Newswire)
Jan-15-26 11:15PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
09:00AM	Loading…
09:00AM	Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect (PR Newswire)
Jan-13-26 11:06PM	3 Reasons to Sell DGX and 1 Stock to Buy Instead (StockStory)
Jan-12-26 09:40AM	Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term (Zacks)
Jan-09-26 02:24PM	Clinical Labs Hope to Head Off Looming Medicare Cuts (Barrons.com)
09:08AM	Is it the Right Time to Add STERIS Stock to Your Portfolio? (Zacks)
07:45AM	Tempus AI Stock Surges 82.4% in a Year: What's Driving It? (Zacks)
Jan-08-26 04:30PM	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 (Business Wire)
10:00AM	Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026 (PR Newswire)
08:27AM	Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now? (Zacks)
07:57AM	Is This the Right Time to Add Resmed Stock to Your Portfolio? (Zacks)
Jan-07-26 09:45AM	Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
07:35AM	Here's Why You Should Add NVST Stock to Your Portfolio Right Now (Zacks)
07:25AM	IDEXX Stock Up 64.7% in a Year: What's Driving the Growth? (Zacks)
Jan-06-26 10:01AM	Data Featuring Haystack MRD from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
08:17AM	Hologic's Breast Health Unit Stays In Focus in 2026: What Lies Ahead? (Zacks)
08:12AM	Should Labcorp Stock Stay in Your Portfolio Right Now? (Zacks)
Jan-05-26 08:58AM	Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan (PR Newswire)
06:51AM	What You Need To Know Ahead of Quest Diagnostics' Earnings Release (Barchart)
Jan-02-26 07:34AM	Is it the Right Time to Add Insulet Stock to Your Portfolio? (Zacks)
Jan-01-26 10:33PM	Q3 Earnings Highlights: Quest (NYSE:DGX) Vs The Rest Of The Testing & Diagnostics Services Stocks (StockStory)
Dec-30-25 12:00PM	Quest Diagnostics (DGX) Upgraded to Buy: Here's Why (Zacks)
Dec-24-25 08:36AM	Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now? (Zacks)
Dec-23-25 09:40AM	Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-19-25 03:20PM	Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-18-25 07:14PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
07:54AM	How Is Henry Schein's Stock Performance Compared to Other Healthcare Stocks? (Barchart)
Dec-17-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-15-25 08:07AM	Quest Diagnostics Stock: Is DGX Outperforming the Healthcare Sector? (Barchart)
Dec-12-25 09:45AM	Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock (Zacks)
Dec-03-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Dec-01-25 09:40AM	Here's Why Quest Diagnostics (DGX) is a Strong Value Stock (Zacks)
08:30AM	Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave Multiple Sclerosis Disease Activity (MSDA) Test Across the United States (Business Wire)
Nov-28-25 11:30AM	Why Is DaVita HealthCare (DVA) Up 1.1% Since Last Earnings Report? (Zacks)
Nov-27-25 11:30AM	Chemed (CHE) Down 5.2% Since Last Earnings Report: Can It Rebound? (Zacks)
08:23AM	HOLX vs. DGX: Which Healthcare Diagnostics Stock Is the Better Bet? (Zacks)
Nov-26-25 09:45AM	Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term (Zacks)
Nov-24-25 07:53AM	Should You Hold Quest Diagnostics Stock in Your Portfolio for Now? (Zacks)
Nov-20-25 11:30AM	Quest Diagnostics (DGX) Up 2.6% Since Last Earnings Report: Can It Continue? (Zacks)
07:08AM	Quest Diagnostics Stock Outlook: Is Wall Street Bullish or Bearish? (Barchart)
Nov-17-25 08:55AM	How Did Tempus AI Power Its Move to Positive EBITDA in Q3? (Zacks)
Nov-14-25 06:16AM	Labcorp inks deal to buy Parkview Health outreach laboratory assets (MedTech Dive)
Nov-13-25 11:49AM	Hims & Hers Bets on Lab Testing to Boost Growth (The Wall Street Journal)
09:40AM	Here's Why Quest Diagnostics (DGX) is a Strong Value Stock (Zacks)
Nov-11-25 07:50PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
04:22PM	Quest Diagnostics Declares Quarterly Cash Dividend (PR Newswire)
Nov-10-25 09:45AM	Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Nov-03-25 04:09PM	Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference (PR Newswire)
Oct-29-25 07:09PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
Oct-27-25 09:40AM	Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term (Zacks)
07:45AM	New Study Demonstrates Accuracy of Two Quest AD-Detect Tests for Alzheimer's Disease Diagnosis (PR Newswire)
Oct-22-25 05:36PM	Quest Diagnostics Incorporated (DGX): A Bull Case Theory (Insider Monkey)
09:45AM	Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock (Zacks)
Oct-21-25 03:07PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
03:02PM	Quest Diagnostics Inc (DGX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
09:29AM	Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise (Zacks)
07:55AM	Quest Diagnostics (DGX) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
06:59AM	Quest (NYSE:DGX) Posts Better-Than-Expected Sales In Q3 (StockStory)
06:52AM	Quest Diagnostics: Q3 Earnings Snapshot (Associated Press Finance)
06:45AM	Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 (PR Newswire)
Oct-19-25 11:07PM	Quest (DGX) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-17-25 09:45AM	Tempus AI Fuels Growth Through Strategic Biotech Collaborations (Zacks)
02:53AM	MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD Technology from Quest Diagnostics (PR Newswire)
Oct-14-25 12:10PM	Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:00AM	Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:38AM	Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings (Zacks)
Oct-13-25 07:58AM	Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus (Zacks)
12:22AM	What to Expect From Quest Diagnostics Next Quarterly Earnings Report (Barchart)
Oct-09-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Oct-03-25 09:45AM	Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term (Zacks)
Oct-01-25 10:17AM	Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing (Zacks)

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to physicians, hospitals, patients, and consumers. The All Other segment consists of risk assessment services and healthcare information technology. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Doherty Catherine T.	Officer	Feb 13 '26	Proposed Sale	207.48	26,165	5,428,714		Feb 13 10:42 AM
Plewman Patrick	SVP for Diagnostic Services	Feb 10 '26	Option Exercise	121.81	5,662	689,660	21,043	Feb 12 04:33 PM
Plewman Patrick	SVP for Diagnostic Services	Feb 10 '26	Sale	204.00	5,662	1,155,048	15,381	Feb 12 04:33 PM
Plewman Patrick	Officer	Feb 10 '26	Proposed Sale	204.00	5,662	1,155,048		Feb 10 12:46 PM
Davis J. E.	CEO and President	Nov 25 '25	Option Exercise	95.80	55,093	5,277,634	175,573	Nov 28 04:30 PM
Davis J. E.	CEO and President	Nov 25 '25	Sale	192.22	55,093	10,589,760	120,480	Nov 28 04:30 PM
Gregg Vicky B	Director	Nov 25 '25	Sale	191.76	1,250	239,700	17,037	Nov 28 04:30 PM
Davis J. E.	Officer	Nov 25 '25	Proposed Sale	192.22	55,093	10,589,762		Nov 25 04:24 PM
Gregg Vicky B	Director	Nov 25 '25	Proposed Sale	191.76	1,250	239,700		Nov 25 09:42 AM
DELANEY MARK E	SVP & Chief Commercial Officer	Nov 18 '25	Option Exercise	144.46	7,946	1,147,845	15,476	Nov 20 04:28 PM
DELANEY MARK E	SVP & Chief Commercial Officer	Nov 18 '25	Sale	187.35	7,946	1,488,683	7,530	Nov 20 04:28 PM
DELANEY MARK E	Officer	Nov 18 '25	Proposed Sale	187.35	7,946	1,488,683		Nov 18 11:02 AM
PFEIFFER GARY M	Director	Oct 22 '25	Sale	182.40	1,482	270,317	29,431	Oct 24 06:10 PM
PFEIFFER GARY M	Director	Oct 22 '25	Proposed Sale	182.40	1,482	270,317		Oct 22 02:10 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 26 '25	Option Exercise	103.57	227	23,510	38,344	Sep 30 04:36 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 26 '25	Sale	188.13	227	42,706	38,117	Sep 30 04:36 PM
PREVOZNIK MICHAEL E	Officer	Sep 26 '25	Proposed Sale	188.13	227	42,706		Sep 26 04:12 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 23 '25	Option Exercise	103.57	28,288	2,929,788	66,405	Sep 25 04:39 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 24 '25	Option Exercise	103.57	175	18,125	38,292	Sep 25 04:39 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 23 '25	Sale	187.12	28,288	5,293,313	38,117	Sep 25 04:39 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 24 '25	Sale	187.02	175	32,729	38,117	Sep 25 04:39 PM
PREVOZNIK MICHAEL E	Officer	Sep 24 '25	Proposed Sale	187.02	175	32,729		Sep 24 04:10 PM
PREVOZNIK MICHAEL E	Officer	Sep 23 '25	Proposed Sale	187.12	28,288	5,293,313		Sep 23 04:14 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 21 '25	Sale	185.00	1,975	365,375	15,269	Aug 25 04:27 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 19 '25	Option Exercise	112.17	4,532	508,354	21,776	Aug 21 04:34 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 19 '25	Sale	183.00	4,532	829,356	17,244	Aug 21 04:34 PM
Plewman Patrick	Officer	Aug 21 '25	Proposed Sale	185.00	1,975	365,375		Aug 21 12:10 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 15 '25	Sale	180.00	1,975	355,500	17,244	Aug 19 04:47 PM
Plewman Patrick	Director	Aug 19 '25	Proposed Sale	183.00	4,532	829,356		Aug 19 04:09 PM
Plewman Patrick	Officer	Aug 15 '25	Proposed Sale	180.00	72	12,960		Aug 15 05:29 PM
Plewman Patrick	Officer	Aug 15 '25	Proposed Sale	180.00	1,903	342,540		Aug 15 05:22 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 06 '25	Option Exercise	86.63	3,560	308,403	24,745	Aug 08 04:40 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 06 '25	Sale	175.00	5,535	968,625	19,219	Aug 08 04:40 PM
Plewman Patrick	Officer	Aug 06 '25	Proposed Sale	175.00	5,535	968,625		Aug 06 01:54 PM
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Jul 30 '25	Option Exercise	102.77	8,269	849,764	15,884	Aug 01 04:37 PM
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Jul 30 '25	Sale	167.40	8,269	1,384,231	10,660	Aug 01 04:37 PM
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Jul 31 '25	Sale	170.00	2,210	375,700	8,450	Aug 01 04:37 PM
KUPPUSAMY KARTHIK	Officer	Jul 31 '25	Proposed Sale	170.00	2,210	375,700		Jul 31 02:27 PM
KUPPUSAMY KARTHIK	Officer	Jul 30 '25	Proposed Sale	167.40	8,269	1,384,231		Jul 30 03:59 PM
DELANEY MARK E	SVP & Chief Commercial Officer	May 12 '25	Sale	175.72	874	153,579	8,372	May 14 05:12 PM
DELANEY MARK E	SVP & Chief Commercial Officer	May 13 '25	Sale	175.31	874	153,221	7,498	May 14 05:12 PM
DELANEY MARK E	Officer	May 13 '25	Proposed Sale	175.31	874	153,221		May 13 09:59 AM
DELANEY MARK E	Officer	May 12 '25	Proposed Sale	175.72	874	153,579		May 12 10:01 AM
Davis J. E.	CEO and President	Apr 02 '25	Sale	168.46	39,191	6,602,074	127,623	Apr 04 08:29 PM
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Apr 02 '25	Sale	170.00	2,555	434,350	10,575	Apr 04 08:26 PM
Davis J. E.	Officer	Apr 02 '25	Proposed Sale	170.00	39,191	6,662,470		Apr 02 10:20 AM
KUPPUSAMY KARTHIK	Officer	Apr 02 '25	Proposed Sale	170.00	2,555	434,350		Apr 02 09:50 AM
PREVOZNIK MICHAEL E	SVP & General Counsel	Mar 17 '25	Sale	170.00	4,643	789,310	38,117	Mar 19 09:00 PM
PREVOZNIK MICHAEL E	Officer	Mar 17 '25	Proposed Sale	170.00	4,643	789,310		Mar 17 10:15 AM
Doherty Catherine T.	EVP, Regional Businesses	Mar 05 '25	Sale	174.13	5,370	935,078	68,068	Mar 07 07:23 PM
Doherty Catherine T.	EVP, Regional Businesses	Mar 04 '25	Sale	175.79	716	125,866	68,068	Mar 05 04:38 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Mar 04 '25	Sale	175.79	592	104,068	38,117	Mar 05 04:35 PM
Doherty Catherine T.	Officer	Mar 05 '25	Proposed Sale	174.13	5,370	935,078		Mar 05 09:59 AM
PREVOZNIK MICHAEL E	Officer	Mar 04 '25	Proposed Sale	175.79	592	104,068		Mar 04 10:20 AM
Doherty Catherine T.	Officer	Mar 04 '25	Proposed Sale	175.79	716	125,866		Mar 04 09:58 AM
PREVOZNIK MICHAEL E	SVP & General Counsel	Feb 27 '25	Sale	172.61	528	91,138	39,031	Feb 28 04:38 PM
Doherty Catherine T.	EVP, Regional Businesses	Feb 27 '25	Sale	172.61	824	142,231	69,178	Feb 28 04:35 PM
Doherty Catherine T.	Officer	Feb 27 '25	Proposed Sale	172.61	824	142,231		Feb 27 10:52 AM
PREVOZNIK MICHAEL E	Officer	Feb 27 '25	Proposed Sale	172.61	528	91,138		Feb 27 10:41 AM
PREVOZNIK MICHAEL E	SVP & General Counsel	Feb 20 '25	Sale	170.99	604	103,278	39,845	Feb 21 04:44 PM
Plewman Patrick	SVP for Diagnostic Services	Feb 19 '25	Sale	169.71	320	54,307	18,082	Feb 21 04:43 PM
Doherty Catherine T.	EVP, Regional Businesses	Feb 20 '25	Sale	170.99	899	153,720	70,457	Feb 21 04:41 PM
Doherty Catherine T.	EVP, Regional Businesses	Feb 19 '25	Sale	169.71	535	90,795	71,356	Feb 21 04:41 PM
PREVOZNIK MICHAEL E	Officer	Feb 20 '25	Proposed Sale	170.99	604	103,278		Feb 20 10:01 AM
Doherty Catherine T.	Officer	Feb 20 '25	Proposed Sale	170.99	899	153,720		Feb 20 09:56 AM

Open in Screener

CELC

Celcuity Inc

Feb 17 • 01:45PM ET

108.51

+4.00 3.83 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD ACAD NBIX BIIB BMRN EXEL ALKS INCY BHVN IONS

| Held by: VTI XBI IWM VXF IWO SCHA VTWO IWC DWAS ITOT

Index	RUT	P/E	-	EPS (ttm)	-3.67	Insider Own	19.50%	Shs Outstand	43.27M	Perf Week	0.57%
Market Cap	5.02B	Forward P/E	-	EPS next Y	-4.08	Insider Trans	1.43%	Shs Float	37.23M	Perf Month	3.07%
Enterprise Value	4.89B	PEG	-	EPS next Q	-1.04	Inst Own	106.48%	Short Float	26.42%	Perf Quarter	26.17%
Income	-162.72M	P/S	-	EPS this Y	-36.17%	Inst Trans	15.12%	Short Ratio	11.64	Perf Half Y	109.52%
Sales	0.00M	P/B	40.15	EPS next Y	-5.90%	ROA	-43.45%	Short Interest	9.84M	Perf YTD	8.79%
Book/sh	2.70	P/C	11.04	EPS next 5Y	30.96%	ROE	-122.04%	52W High	120.32 -9.81%	Perf Year	742.47%
Cash/sh	9.83	P/FCF	-	EPS past 3/5Y	-8.60% -31.53%	ROIC	-37.22%	52W Low	7.57 1332.48%	Perf 3Y	839.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.45% 5.85%	Perf 5Y	547.43%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-40.75%	Oper. Margin	-	ATR (14)	5.90	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.26	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.99	Recom	1.18
Dividend Gr. 3/5Y	- -	Current Ratio	12.26	EPS Q/Q	-32.20%	SMA20	-0.26%	Beta	0.41	Target Price	114.20
Payout	-	Debt/Eq	2.74	Sales Q/Q	-	SMA50	2.76%	Rel Volume	0.51	Prev Close	104.51
Employees	87	LT Debt/Eq	2.74	Earnings	Nov 12 AMC	SMA200	86.58%	Avg Volume	845.10K	Price	108.51
IPO	Sep 20, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.68% -	Trades		Volume	289,464	Change	3.83%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-25	Initiated	Wells Fargo	Overweight	$126
Nov-18-25	Initiated	Wolfe Research	Outperform	$110
Nov-17-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-22-25	Initiated	Guggenheim	Buy	$110
Jul-01-25	Resumed	Stifel	Buy	$30
Jul-22-24	Initiated	Leerink Partners	Outperform	$29
Feb-22-24	Initiated	Stifel	Buy	$40
Dec-08-23	Initiated	H.C. Wainwright	Buy	$27
Oct-08-21	Initiated	Canaccord Genuity	Buy	$50
Sep-07-21	Initiated	Jefferies	Buy	$48
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy	$50
Jan-28-21	Reiterated	H.C. Wainwright	Buy	$14 → $18
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$11 → $14
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy	$36

Show Previous Ratings

Feb-13-26 09:40AM	Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-12-26 04:05PM	Celcuity Appoints Charles Romp to its Board of Directors (GlobeNewswire)
Feb-11-26 11:42PM	Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference (MarketBeat)
Feb-04-26 07:05AM	Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Feb-02-26 09:33AM	Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances (Insider Monkey)
09:40AM	Loading…
Jan-27-26 09:40AM	Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-20-26 07:30AM	Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer (GlobeNewswire)
Jan-11-26 12:59AM	Wells Fargo Initiates Coverage On Celcuity Inc. (CELC) (Insider Monkey)
Jan-06-26 11:47AM	Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? (Zacks)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-11-25 08:24PM	Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank (Zacks)
02:35PM	Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-03-25 04:43PM	3 Stocks You'll Wish You Bought Before 2026 (MarketBeat) +5.87%
Nov-26-25 04:05PM	Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium (GlobeNewswire)
07:05AM	Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference (GlobeNewswire)
07:02AM	Loading…
Nov-23-25 07:02AM	Celcuity (CELC)'s Clinical Success and M&A Potential Underpin Wolfe Research's Bullish View (Insider Monkey)
Nov-18-25 09:35AM	Block upgraded, Dell downgraded: Wall Streets top analyst calls (TipRanks)
Nov-17-25 04:05PM	Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer (GlobeNewswire)
09:34AM	Block upgraded, Dell downgraded: Wall Street's top analyst calls (The Fly)
Nov-13-25 12:01AM	Celcuity Inc (CELC) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-12-25 04:01PM	Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.56%
Nov-06-25 10:08AM	Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. (Investor's Business Daily)
10:03AM	Celcuity Eyeing Cancer Treatment Riddle. Stock Flies 534% This Year. (Investor's Business Daily)
Nov-05-25 07:05AM	Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Nov-04-25 07:05AM	Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference (GlobeNewswire)
Nov-03-25 05:22AM	ESMO 2025: Celcuity gets first positive results for Pi3K inhibitor in PiK3CA wild-type HR+/HER2 breast cancer (Clinical Trials Arena)
Oct-21-25 12:55PM	Celcuity (CELC) Hits Fresh Record High on Stellar Breast Cancer Drug Trial Result (Insider Monkey) -7.20%
Oct-20-25 04:13PM	Top 1% Celcuity Stock Shoots To Record High On Roche-Rivaling Breast Cancer Results (Investor's Business Daily) +35.84%
10:02AM	Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results (Investor's Business Daily)
Oct-18-25 04:30AM	Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
04:30AM	Loading…
04:30AM	Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial (GlobeNewswire)
04:30AM	Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer ("mCRPC") (GlobeNewswire)
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire)
Sep-30-25 12:47PM	Celcuity Inc. (CELC)'s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review (Insider Monkey) -5.13%
Sep-22-25 09:15AM	Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
Sep-09-25 04:01PM	Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance (GlobeNewswire) -7.96%
Aug-27-25 04:05PM	Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program (GlobeNewswire) +9.29%
Aug-15-25 03:24AM	Celcuity Inc (CELC) Q2 2025 Earnings Call Highlights: Navigating Losses and Strategic Advances (GuruFocus.com)
Aug-14-25 04:01PM	Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 07:05AM	Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jul-30-25 06:30AM	Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire)
02:15PM	Up 215% YTD, Should You Grab This Growth Stock Before Its Too Late? (Barchart)
09:56AM	Relay Therapeutics has positive read from Celcuity data, says Barclays (TipRanks)
09:43AM	Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial (Insider Monkey)
Jul-28-25 04:02PM	Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock (GlobeNewswire) +167.18%
02:09PM	Celcuity stock rallies on Phase III breast cancer trial progress (Clinical Trials Arena)
11:55AM	Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More (Investopedia)
10:09AM	Celcuity Stock Triples on Positive Breast Cancer Treatment Study (Investopedia)
09:42AM	Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer (Benzinga)
08:15AM	Celcuity shares triple on late-stage results for breast cancer therapy (BioPharma Dive)
07:00AM	Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ("PFS") Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial (GlobeNewswire)
Jul-25-25 04:05PM	Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
Jul-24-25 04:01PM	Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
Jul-14-25 07:05AM	Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 (GlobeNewswire)
Jun-30-25 07:05AM	Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib (GlobeNewswire) +6.46%
May-21-25 07:05AM	Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences (GlobeNewswire)
May-15-25 09:56AM	Q1 2025 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Celcuity Inc (CELC) Q1 2025 Earnings Call Highlights: Navigating Increased Losses and Strategic ... (GuruFocus.com)
May-14-25 04:01PM	Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 07:05AM	Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Apr-01-25 08:41AM	Q4 2024 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) -8.11%
07:05AM	Celcuity To Present at Upcoming Needham and Stifel Investor Conferences (GlobeNewswire)
03:03AM	Celcuity Inc (CELC) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... (GuruFocus.com)
Mar-31-25 10:50PM	Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:01PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-25 07:05AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-25-25 07:05AM	Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences (GlobeNewswire) -8.99%
Dec-11-24 07:05AM	Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-15-24 02:20AM	Celcuity Inc (CELC) Q3 2024 Earnings Call Highlights: Clinical Milestones and Financial Challenges (GuruFocus.com) -10.28%
Nov-14-24 04:01PM	Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-12-24 07:05AM	Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences (GlobeNewswire)
Nov-07-24 07:05AM	Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Oct-09-24 06:26PM	Celcuity Inc (CELC) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses (GuruFocus.com) -5.83%
Oct-07-24 09:10PM	Morgan Stanley's Strategic Reduction in Celcuity Inc Holdings (GuruFocus.com)
Sep-10-24 09:55AM	Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-20-24 12:00PM	Celcuity (CELC) Upgraded to Buy: Here's Why (Zacks)
Aug-14-24 04:01PM	Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 07:05AM	Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jun-03-24 04:01PM	Celcuity To Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -5.25%
May-30-24 07:36AM	Celcuity Announces Pricing of Underwritten Common Stock Offering (GlobeNewswire)
07:00AM	Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing (GlobeNewswire)
May-16-24 11:54AM	Craig-Hallum Adjusts Price Target on Celcuity to $27 From $25, Assumes Buy Rating (MT Newswires)
03:08AM	Celcuity Inc (CELC) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ... (GuruFocus.com)
May-15-24 08:55PM	CELC Stock Earnings: Celcuity Beats EPS for Q1 2024 (InvestorPlace)
06:04PM	Celcuity Q1 Net Loss Widens; Shares Rise After Hours (MT Newswires)
04:01PM	Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 07:05AM	Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire)
Apr-04-24 07:05AM	Celcuity To Present at Upcoming Needham and Stifel Investor Conferences (GlobeNewswire)
Apr-01-24 01:38PM	Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 06:51AM	Q4 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) +18.94%
Mar-27-24 08:53PM	CELC Stock Earnings: Celcuity Beats EPS for Q4 2023 (InvestorPlace)
05:51PM	Celcuity Inc (CELC) Reports Full Year 2023 Financial Results and Highlights Key Developments (GuruFocus.com)
04:01PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-21-24 11:17AM	Why Celcuity (CELC) Might Surprise This Earnings Season (Zacks)
Mar-20-24 07:05AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Mar-06-24 07:05AM	Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-28-24 07:05AM	Celcuity to Participate in Cowen's 44th Annual Health Care Conference (GlobeNewswire)

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dalvey David	Director	Jan 27 '26	Sale	120.03	20,000	2,400,538	90,000	Jan 29 04:31 PM
Dalvey David	Director	Jan 27 '26	Proposed Sale	120.03	20,000	2,400,538		Jan 27 12:21 PM
Buller Richard E	Director	Dec 05 '25	Option Exercise	5.50	3,000	16,500	9,760	Dec 09 04:23 PM
Buller Richard E	Director	Dec 05 '25	Sale	105.69	3,000	317,070	6,760	Dec 09 04:23 PM
Furcht Leo	Director	Dec 04 '25	Option Exercise	7.60	250	1,900	11,000	Dec 08 04:30 PM
Buller Richard E	Director	Dec 05 '25	Proposed Sale	105.68	3,000	317,040		Dec 05 05:31 PM
Buller Richard E	Director	Dec 01 '25	Option Exercise	14.83	1,100	16,313	8,360	Dec 03 04:09 PM
Buller Richard E	Director	Dec 01 '25	Sale	98.13	1,100	107,948	7,260	Dec 03 04:09 PM
Buller Richard E	Director	Dec 01 '25	Proposed Sale	98.13	1,100	107,943		Dec 01 05:46 PM
Dalvey David	Director	Nov 21 '25	Sale	100.00	15,000	1,500,016	110,000	Nov 24 04:07 PM
Buller Richard E	Director	Nov 20 '25	Option Exercise	14.83	3,900	57,837	11,160	Nov 21 04:14 PM
Buller Richard E	Director	Nov 20 '25	Sale	96.73	3,900	377,255	7,260	Nov 21 04:14 PM
Dalvey David	Director	Nov 21 '25	Proposed Sale	100.00	15,000	1,500,016		Nov 21 01:41 PM
Buller Richard E	Director	Nov 20 '25	Proposed Sale	96.73	3,900	377,255		Nov 20 04:33 PM
BAKER BROS. ADVISORS LP	10% Owner	Sep 08 '25	Buy	56.27	170,100	9,571,319	7,211,484	Sep 10 04:06 PM
Dalvey David	Director	Jul 28 '25	Sale	43.98	100,000	4,397,603	125,000	Jul 30 04:15 PM
Dalvey David	Director	Jul 28 '25	Sale	45.12	9,325	420,767	0	Jul 30 04:15 PM
Brightstone Venture Capital Fu	Director	Jul 28 '25	Proposed Sale	43.98	100,000	4,397,605		Jul 28 02:52 PM
Dalvey David	Director	Jul 28 '25	Proposed Sale	45.12	9,325	420,766		Jul 28 02:00 PM

CSTL

NTRA

EXAS

LH

VCYT

SERA

GH

XGN

PSNL

DGX

CELC

Upgrade your FINVIZ experience